




**Joint Brachytherapy Meeting
GEC/ESTRO – ABS – GLAC**

Barcelona, May 14-15, 2004

**Pre-meeting Workshop on
“Advances in Image-based Brachytherapy”**

Barcelona, May 13, 2004

PROGRAMME AND EXHIBITION GUIDE



Content

Committees	4
Acknowledgements	5
Award lectures	6
General information	7
Technical exhibition – participants (alphabetical)	10
Technical exhibition – participants	14
Technical exhibition – floor plan	15
Scientific Programme Workshop	17
Scientific Programme Meeting	21
Friday, May 14, 2004	23
Saturday, May 15, 2004	35
Posters	47
Index authors	75

COMMITTEES

SCIENTIFIC COMMITTEE

M. de la Torre
B. Erickson
F. Guede
G. Kovacs
H. Marsiglia
J.J. Mazon
R. Pötter
M. Zelefsky

LOCAL ORGANISING COMMITTEE

F. Guede
A. Roviro
A. Biete
J. Craven-Bartle
I. Herruzo
J.L. Guinot
I. Monteiro-Grillo
V. Munos
A. Palacios
A. Ramos
P. Fernandez
N. Stas

chairperson – Barcelona
chairperson – Barcelona
Barcelona
Barcelona
Malaga
Valencia
Lisboa
Vigo
Cordoba
Madrid
San Sebastian
Porto

ACKNOWLEDGEMENTS

ESTRO, the European Society for Therapeutic Radiology and Oncology, wishes to thank for their support to this meeting :

Advanced Care Technologies
Bard Limited
GlaxoSmithKline
Nucletron BV
Oncura, an Amersham Business
Varian Medical Systems

All companies having supported the participation of some delegates in this meeting and/or participating in the technical exhibition

Ferran Guedea and the members of the local organising committee for having gracefully accepted to host the pre-meeting workshop on "Advances in Image-based Brachytherapy" and the third edition of the "Joint Brachytherapy Meeting".

AWARD LECTURES

ESTRO-Nucletron Best Junior Presentation

Friday May 14, 2004 – 11:50

Auditorium

Intercomparison of treatment concepts for 3D image guided brachytherapy of cervical carcinoma based on a gec-estro study protocol

S. Lang (Austria)

The Marie-Curie Medal

Friday May 14, 2004 – 12:00

Auditorium

Following my way in Curie therapy - Tarragona 1950 through Houston 1996

L. Delclos (U.S.A.)

ESTRO-Nucletron Brachytherapy Award

Saturday May 15, 2004 – 17:10

Auditorium

Chronic toxicity profile and biochemical outcome in favorable-stage prostate cancer patients undergoing monotherapy with HDR or LDR (Pd103) brachytherapy at William Beaumont Hospital

M. Ghilezan (USA)

GENERAL INFORMATION

VENUE OF THE MEETING

World Trade Centre Barcelona
Moll de Barcelona
08039 Barcelona
Spain
Tel: +34.93.508.81.25 – Fax: +34.93.508.80.75
Website: <http://www.wtcbarcelona.com>

ACCOMMODATION

Mundi Travel is the officially appointed accommodation agent for the meeting.

Viajes Munditravel s.l.
Att. Daniel Dal Monte
Fax : +34.93.457.92.91
E-mail : d.dalmonete@munditravel.es

ACCREDITATION

The Joint Brachytherapy meeting GEC/ESTRO-ABS-GLAC has been reviewed and approved by the Accreditation Council of Oncology in Europe (ACOE).

The meeting is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.be

The Joint Brachytherapy meeting GEC/ESTRO-ABS-GLAC has been awarded maximum 23 CME credit points. Each specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credits to AMA PRA Category 1 credits, contact the AMA (<http://www.ama-assn.org>).

BADGES

Upon registration you will receive a personal badge. You are kindly requested to wear this badge when attending scientific sessions and/or social events, and when entering the exhibition area.

CATERING

Coffee break

Coffee will be served during the breaks in the exhibition area in the Agora Hall. All participants will receive free coffee, tea and refreshments upon presentation of their badge.

Lunch

Lunch will be served from Thursday May 13 to Saturday May 15 in the exhibition area.

POSTERS

Posters will be on display throughout the meeting.

The author's presence at the poster board is required during lunch time from 13.30 to 14.30 for the following poster numbers:

On Friday: 14 May 2004 nr 2 – 192 and 298 - 332

On Saturday: 15 May 2004 nr 193 - 297

Posters should be removed by the author before 19.15 h on Saturday May 15. All remaining posters will be removed by the organisers and can NOT be recuperated.

SATELLITE SYMPOSIA

Lunchtime:

Thursday, May 13, 2004 (pre-meeting workshop)
- Bard Limited

Lunchtime:

Friday, May 14, 2004
- Oncura

Lunchtime:

Saturday, May 15, 2004
- Nucletron

SOCIAL PROGRAMME

Welcome Reception *Thursday, May 13, 2004*

The welcome reception, to which all participants and company delegates are invited, will be held in the "Palau de la Musica Catalana", a modernist building of great beauty designed by the architect Monèch I Montaner.

ESTRO gratefully acknowledges the support of Varian.

Conference Banquet *Saturday, May 15, 2004*

All participants are invited to the Gala dinner which will be organised at the "Museu Maritim de Barcelona/Marques de Comillas".

How to get there:

The Museum is located at walking distance form the World Trade Center.

For participants located in an other area than the World trade Center:

Underground Line 3, Drassanes station. Buses: 14, 18, 36, 38, 57, 59, 64 and 91

EXHIBITION

The exhibition will open for participants from:

- Thursday May 13 10:00 – 18:00
- Friday May 14 09:15 – 17:30
- Saturday May 15 09:30 – 17:30

DRESS

Informal on all occasions.

MEETING SECRETARIAT

After the meeting

ESTRO office
Av. E. Mounierlaan 83
1200 Brussels
Belgium
Tel: 32.2.775 93 40
Fax: 32.2.779 54 94
E-mail: info@estro.be

PROJECTION

Only PowerPoint projection is available.

TECHNICAL EXHIBITION

Advanced Care Technologies Mrs. Lindsey Raymond 115 Hurley Road, Building3A Oxford CT 6478 U.S.A. Tel.: 12032624194 Fax: 12032624193 E-mail: lraymond@acp-ct.com	1
BARD Limited Mr. Kelly Neill Forest House, Brighton Road Crawley, West Sussex RH11 9BP United Kingdom Tel.: 44.1293.606674 Fax: 44.1293.552428 E-mail: Kelly.neill@crbard.com	14
BEBIG GmbH Mrs. Karolin Riehle Robert Rössle-str. 10 13125 Berlin Germany Tel.: 49.30.9410840 Fax: 49.30.941084150 E-mail: karolin.riehle@ezag.de	7 -8
Best Medical International Mr. Manny Suramian 7643 Fullerton Road Springfield VA 22153 USA Tel.: 1.703.4512378 Fax: 1.703.4515228	19
BSD Medical Corporation Mrs. Tiffany Christensen 2188 West 2200 South Salt Lake City Utah 84119-1326 U.S.A. Tel.: 18019725555 Fax: 18019725930 E-mail: info@bsdmc.com	19bis


Computerized Medical Systems (CMS) GmbH Mrs. Friederike Schreiber Sundgauallee 25 79114 Freiburg Germany Tel.: 49.761.881880 Fax: 49.761.8818811 E-mail: friederike.schreiber@cms-euro.com www: www.cms-euro.com	16
Draximage Mrs. Janet Soule 16751 TransCanada Hwy. Kirkland-Quebec H9H 4J4 Canada Tel.: 15146307067 Fax: 15146307073 E-mail: j.soule@draximage.com	5
Implant Sciences Corporation Mrs. Catherine Hiscock 107 Audubon Road, #5 Wakefield MA 01880 U.S.A. Tel.: 17812460700 ext 125 Fax: 17812461167 E-mail: chiscock@implantsciences.com	18
Isodose Control BV Eric van 't Hooft Landjuweel 11 Veenendaal 3905 PE The Netherlands Tel.: 31.318.502950 Fax.: 31.318.502528 E-mail: evanthoof@cs.com	21
Mentor Corporation Mr. Nick O'Malley 201 Mentor Drive Santa Barbara CA 93111 U.S.A. Tel.: 18058796448 Fax: 18058796002 E-mail: domalley@mentorcorp.com www: www.mentorcorp.com	15




- North American Scientific, Inc. 20
Mrs. Erin Neilson
20200 Sunburst Street
Chatsworth CA 91311
U.S.A.
Tel.: 18187348600
Fax: 18187725257
E-mail: erin.neilson@nasi.net
- Nucletron B.V. 9 & 12
Mrs. Jeske van der Sluijs
Waardgelders 1
3905 TH Veenendaal
The Netherlands
Tel.: 31.318.557225
Fax: 31.318.557280
E-mail: congress@nucletron.nl
www: www.nucletron.com
- ONCURA – an Amersham Business 10-11
Mr Saheed Rashid
The Grove Centre
White Lion Road
Amersham, Buckinghamsh HP7 9LL
United Kingdom
Tel.: 44.1494.546251
Fax: 44.1494546264
E-mail: sandra.needham@oncura.com
www: www.amersham.com
- Proxima Therapeutics, Inc. 6
Mr. Kirk Mundy
2555 Marconi Drive, Suite 220
Alpharetta, GA 30005-2066
U.S.A.
Tel.: 1.770.7534848 ext. 208
Fax: 1.770.7534937
E-mail: kmundy@proximatherapeutics.com
www: www.proximatherapeutics.com
- Simuplan 17
Mr. Conrado PLA
Miguel Hernandez 25
LA Eliana - Valencia 46183
Spain
E-mail: cpla@simuplan.com

- Theragenics Corporation 2
Ms. Ann Lane
5203 Bristol Industrial Way
Buford, Georgia GA 30518
U.S.A.
Tel.: 1.770.8315134
Fax: 1.678.4824909
E-mail: lanea@theragenics.com
www: www.theragenics.com
- Thomson / Nielsen Electronics 4
Mrs. Sarah Taylor
25 E Northside Rd.
Ottawa, ON K2H 8S1
Canada
Tel.: 16135964563 ext101
Fax: 161359165243
E-mail: staylor@thomson-elec.com
www: www.thomson-elec.com
- Tyco Healthcare 3
Mrs. Isabelle Fafournoux
2 rue Denis Diderot,
ZA le clef de Saint Pierre
Elancourt 78990
France
Tel.: 33130798438
Fax: 33130798213
E-mail: fafournouxl@tycohealth.com
- Varian Medical Systems 13
Dr. Armin Mader
Alsfelder Strasse 6
64289 Darmstadt
Germany
Tel.: 49.6151.731315
Fax: 49.6151.731313
E-mail: armin.mader@varian.com

TECHNICAL EXHIBITION

1	Advanced Care Technologies
2	Theragenics Corporation
3	Tyco Healthcare
4	Thomson / Nielsen Electronics
5	Draximage
6	Proxima Therapeutics, Inc.
7-8	BEBIG GmbH
9	Nucletron B.V.
10-11	ONCURA – an Amersham Business
12	Nucletron B.V.
13	Varian Medical Systems
14	BARD Limited
15	Mentor Corporation
16	Computerized Medical Systems (CMS) GmbH
17	Simuplan
18	Implant Sciences Corporation
19	Best Medical International
19bis	BSD Medical Corporation
20	North American Scientific, Inc.
21	Isodose Control B.V.








THURSDAY, 13 MAY 2004
WORKSHOP
**ADVANCES IN IMAGE-BASED
BRACHYTHERAPY**




- Directors: C. Haie-Meder (F)
R. Pötter (A)
M. Zelefsky (USA)
- 08.00-10:15 **Advances in oncologic imaging and its impact on treatment planning for prostate**
Moderator: J. Battermann (NL)
- 08.00 Limitations of CT-based target contours for post-implant evaluation after LDR-BRT.
Results of an ABS post-implant contouring workshop
W.R. Lee (USA)
- 08.20 Limitations of CT-based target contours for post-implant evaluation after LDR-BRT British study
D. Ash (UK)
- 08.40 Advanced transrectal ultrasound imaging in treatment planning
B. Carey (UK)
- 09.00 Enhanced prostate imaging with MRI and MRSI
S. Eberhardt (USA)
- 09.20 Impact of MRI on brachytherapy treatment planning
R.W. McLaughlin (USA)
- 09.40 MRSI-Guided dose escalation for LDR brachytherapy.
Outcome and tolerance
M. Zelefsky (USA)
- 10.00 Discussion
- Coffee Break
- 10.45-13.15 **Dose volume parameters in target evaluation in brachytherapy: coming to a consensus ?**
Moderator: J.L.F. Da Silva (BR)
- 10.45 What is expected variation and predictors of target coverage ?
What is an adequate implant ?
P. Lavagnini (I)
- 11.00 What is expected variation and predictors of target coverage ?
What is an adequate implant ?
B.R. Prestidge (USA)
- 11.15 Conclusion

- 11.25 *Moderator: F.A. Vicini (USA)*
What is expected variation and predictors of target coverage ?
What is an adequate implant ?
E. Van Limbergen (B)
- 11.40 What is expected variation and predictors of target coverage ?
What is an adequate implant ?
D. Arthur (USA)
- 11.55 Conclusion
- Moderator: R. Pötter(A)*
- 12.05 What is expected variation and predictors of target coverage ?
What is an adequate implant ?
C. Haie-Meder (F)
- 12.20 What is expected variation and predictors of target coverage ?
What is an adequate implant ?
B. Erickson (USA)
- 12.35 Discussion
- 12.45 Conclusion
- 13.15-15.15 Lunch
- 15.15-17.30 **Dose-volume parameters in organs at risk in brachytherapy:
coming to a consensus ?**
Moderator: L. Potters (USA)
- 15.15 What are acceptable normal tissue dose volume constraints for
prostate brachytherapy ?
J. Crook (CDN)
- 15.30 What are acceptable normal tissue dose volume constraints for
prostate brachytherapy ?
R. Stock (USA)
- 15.45 Discussion
- Moderator: S. Zunino (AR)*
- 15.55 What are acceptable normal tissue constraints for gynaecology ?
I. Barillot (F)
- 16.10 What are acceptable normal tissue constraints for gynaecology ?
P. Eifel (USA)
- 16:25 Discussion

- Moderator: J. White (USA)*
- 16.35 What are acceptable normal tissue constraints for breast brachytherapy ?
D.E. Wazer (USA)
- 16.50 What are acceptable normal tissue constraints for breast brachytherapy ?
V. Strnad (D)
- 17.05 Discussion
17.15 General Discussion
- 18.00-19.00 **Morbidity scoring criteria for brachytherapy: suggestions for the future ?
Limitations of currently used scoring systems**
- 18.00 The French-Italian glossary vs the CTCAEv3.0
E. Barillot (F)
- 18.20 Late urinary morbidity. The status of scoring systems and a collaborative proposal for prostate cancer
D.J. Demanes (USA)
- 18.40 Discussion
18.55 Summary



SCIENTIFIC PROGRAMME



FRIDAY 14 MAY

Refresher course



Auditorium and Room B 08:00 - 08:30 Abstract N°

moderator: A. Rovirosa (Spain)

08:00	GEC-ESTRO: Patterns of care for brachytherapy in Europe (PCBE) <i>F. Guedea (Spain)</i>	1
08:14	Current status of brachytherapy facilities and applications in Poland <i>W. Bulski, A. Walczak, J. Lyczek, M. Kawczynska (Poland)</i>	2
08:18	Patterns of Care for Brachytherapy in Europe (PCBE): results in Spain <i>J. López Torrecilla, F. Guedea, R. Nisin, T. Ellison (Spain)</i>	3
08:22	Results of the PCBE questionnaire – 2002 in France <i>D. Peiffert, F. Guedea, J.J. Mazon, R. Nisin, National Cancer Analysis Team (France)</i>	4
08:26	Results of the PCBE questionnaire-2002 in The Netherlands <i>J. Venseelaar, F. Guedea, B.J. Slotman, T. Ellison, R. Nisin (The Netherlands)</i>	5

Auditorium 08:30 - 09:30

moderator: A. Poitevin (Tlalpan, Mexico)

08:30	GLAC: Combined chemoradiotherapy and brachytherapy in locally advanced cervical cancer <i>M. de la Torre (Argentina)</i>	6
	moderator: L. Linares (New Orleans LA, U.S.A.)	
09:00	ABS: What have we learned from long-term results of prostate brachytherapy <i>P. Grimm (U.S.A.)</i>	7
09:30	Coffee	



FRIDAY 14 MAY

Proffered papers



Room B 08:30 - 09:30 Abstract N°

Physics: prostate

moderator: K.I. Kolkman-Deurloo (The Netherlands)
 moderator: G.N. Cohen (USA)

08:30	A prostate phantom for quality control of MR and CT based postimplant seed reconstruction <i>M. De Brabandere, C. Kirisits, S. Lang, J. Venselaar, D. Georg, D. Huyskens (Belgium)</i>	8
08:40	Assessment of prostate volume determining parameters in I-125 therapy <i>R. Westendorp, A. van 't Riet, R. Bouwman, L. Elders, C. Hoekstra, J. Immerzeel, F. Ypma (The Netherlands)</i>	9
08:50	Time-integrated DVH for clinical post-implant dosimetric assessments in I-125 permanent prostate brachytherapy <i>G. Leclerc, M.-C. Lavallé, A.-G. Martin, E. Vigneault, L. Beaulieu (Canada)</i>	10
09:00	Automatic seed localization, using MR images, for post implant assessment following prostate seed implantation <i>E. Holupka, N.B. Bloch, I.D. Kaplan, G. Mathiowitz, A. Mahadevan, T.H. Helbich, R. Oismueller, R. Hawliczek, R. Cormack, P.M. Meskell (U.S.A.)</i>	11
09:10	A comparison of automated and manual dose-volume data extraction for HDR prostate patients: implications for tolerance data <i>J. Hanley, I. Rebo, A. Kapulsky, A.M. Ndlovu, J.J. Napoli, G. Gejerman (U.S.A.)</i>	12
09:20	A systematic quality control of seed dosimetry with an automatic needle loading system for permanent prostate implant <i>J. Morrier, N. Varfalvy, M.-C. Lavallée, L. Beaulieu (Canada)</i>	13
09:30	Coffee	

FRIDAY

Proffered papers

FRIDAY 14 MAY

Proffered papers



Auditorium 10:00 - 12:00

Abstract N°

Cervix Cancer

moderator: I. Barillot (France)
 moderator: M.J. Da Rocha Alves (Brasil)
 moderator: H. Stankusova (Czech Republic)

10:00	Long-term results of a randomised trial comparing two preoperative low dose-rates brachytherapy in patients with cervix cancer <i>C. Haie-Meder, A. Kramar, H. El Boussairi, J. Bouzy, M. Albano, P. Morice (France)</i>	14
10:10	Retrospectively analysis of 449 cervical cancers treated with High-voltage Beam-Irridiation (EBRT) and High-Dose-Rate afterloading (HDR) <i>G. Haensgen, H. Strauss, D. Utzig, J. Dunst (Germany)</i>	15
10:20	Advanced cervical carcinoma treated by external beam radiotherapy and high dose rate brachytherapy <i>P.E.R.S. Novaes, R. Ferrigno, A.C.A. Pellizzon, M.A.C. Maia, R.C. Fogaroli, J.V. Salvajoli (Brasil)</i>	16
10:30	High dose rate brachytherapy in the management of cervix cancer <i>P. Nanavati, J. Shaffer, M. Crispens, J. Wynstra, E. Elliott, R. Maxey, C. Frierdich, S. VanderMeersch (U.S.A.)</i>	17
10:40	Comparison of twelve-year treatment results of advanced cervical carcinoma with Californium-252 vs. gamma radiation only in brachytherapy <i>T. Tacev, B. Ptackova, V. Strnad (Czech Republic)</i>	18
10:50	LDR interstitial brachytherapy in the management of carcinoma of the cervix <i>S. Nag, C. Sitathane, I. Ben-Shachar, J. Fowler (U.S.A.)</i>	19
11:00	Systematic evaluation of MRI and clinical findings in cervical cancer at diagnosis and at time of brachytherapy: potential of MRI on delineation of GTV, patho-anatomical structures and organs at risk <i>J. Dimopoulos, G. Schard, C. Kirisits, S. Lang, G. Goldner, S. Wachter, N. Wachter-Gerstner, T. Helbich, R. Pötter (Austria)</i>	20



FRIDAY, 14 MAY

Proffered papers



Abstract N°

- | | | |
|-------|--|----|
| 11:10 | Imaging the non-displaced rectosigmoid during HDR brachytherapy for cervical cancer can alter dose specification
<i>B. Erickson, L. Grossheim, J. Mai, S. Firat, K. Murray, J. Rownd (U.S.A.)</i> | 21 |
| 11:20 | Dose parameters for MRI based treatment planning – Analysis of 93 individual fractions in HDR cervix cancer brachytherapy for 22 patients
<i>C. Kirisits, S. Lang, J. Dimopoulos, N. Wachter-Gerstner, D. Georg, R. Pötter (Austria)</i> | 22 |
| 11:30 | Combined MRI-based intracavitary and interstitial brachytherapy for locally advanced cervical cancer with a modified tandem ring applicator- Clinical feasibility and preliminary results
<i>J. Dimopoulos, S. Lang, C. Kirisits, J. Böswarth, N. Bauer, N. Wachter-Gerstner, T. Knocke, R. Pötter (Austria)</i> | 23 |
| 11:40 | Initial clinical results of inverse planned high dose rate interstitial implants for cervical cancer
<i>K. Huang, J. Pouliot, E. Lessard, V. Weinberg, J. Speight, L. Chen, I. Hsu (U.S.A.)</i> | 24 |
| 11:50 | Intercomparison of treatment concepts for 3D image guided brachytherapy of cervical carcinoma based on a GEC-ESTRO study protocol
<i>S. Lang, A. Nulens, E. Briot, C. Kirisits, M. De Brabandere, I. Dumas, J. Dimopoulos, N. Wachter-Gerstner, P. Petrow, E. Van Limbergen, C. Haie-Meder, R. Pötter (Austria)</i> | 25 |

FRIDAY 14 MAY

Symposia



Room B 10:00 - 12:00 Abstract N°

TG43 and calibration

moderator: J. Perez-Calatayud (Spain)
 moderator: T. Hellebust (Norway)

TG 43

10:00	Consideration of the updated TG-43 brachytherapy dosimetry formalism <i>M.J. Rivard (U.S.A.)</i>	26
10:30	Clinical validation of TG-43 data treatment planning algorithms <i>A.S. Meigooni (U.S.A.)</i>	27
10:45	Pitfalls in the use of TG-43 in brachytherapy treatment planning, some examples <i>R. Van der Laarse (The Netherlands)</i>	28
11:00	3D Imaging based treatment planning in brachytherapy, the next generation or what next to TG-43 <i>D. Baltas, G. Anagnostopoulos, N. Milickovic (Germany)</i>	29

Calibration

11:20	The differences in approach to source calibration between the US and the EU <i>B. Thomadsen, L. DeWerd (U.S.A.)</i>	30
11:40	Primary standards for brachytherapy sources, emitting betas and low energy photons <i>E. van Dijk (The Netherlands)</i>	31



FRIDAY 14 MAY

Award lecture



Auditorium 12:00 - 12:30

Abstract N°

moderator: M. Zelefsky (New York, U.S.A.)
introduction: A. Gerbaulet (Villejuif, France)

Following my way in Curie therapy - Tarragona 1950 through
Houston 1996 32
L. Delclos (U.S.A.)

12:30 Lunch



FRIDAY 14 MAY

Proffered papers



Auditorium 14:30 - 16.30

Abstract N°

Prostate Cancer: disease control

moderator: P. Hoskin (United Kingdom)
 moderator: B. Davis (USA)

14:30	Prostate cancer patients treated with external beam radiation therapy combined with I125/Pd103 brachytherapy: Seattle's fifteen year outcome results <i>J.E. Sylvester, J.C. Blasko, P.D. Grimm, R. Meier, J.A. Malmgren (U.S.A.)</i>	33
14:40	Long term outcome following Iodine-125 permanent seed implant for localised prostate cancer: Leeds experience <i>J. Joseph, B. Al-Qaisieh, D. Ash, D. Bottomley, B. Carey, K. Gould (United Kingdom)</i>	34
14:50	Early biochemical outcome following permanent interstitial brachytherapy as monotherapy in T1-T2 prostate cancer: results of a collaborative group on prostate brachytherapy <i>N. Salem, S. Langley, F. Guedea, L. Nava, V. Kataja, U. Maurer, F. Bladou, R. Laing, F. Aguilo, N. Di Muzio (France)</i>	35
15:00	Results of high dose rate (HDR) brachytherapy boost for prostate cancer <i>D. Kelly, J. Flynn, W. Brookover (U.S.A.)</i>	36
15:10	Comparison of 5-year outcomes between conformal LDR brachytherapy and high dose IMRT for patients with clinically localized prostate cancer <i>M. Zelefsky, J. Yamada, Z. Fuks, H. Chan, G. Cohen, M. Zaider, S. Leibel (U.S.A.)</i>	37
15:20	Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external beam radiation <i>D. Reed, G. Merrick, W. Butler, K. Wallner, R. Galbreath, J. Lief, E. Adamovich (U.S.A.)</i>	38



FRIDAY, 14 MAY

Proffered papers



FRIDAY

Proffered papers

Abstract N°

15:30	Improved biochemical relapse-free survival for patients with large/wide glands treated with prostate seed implantation for low and intermediate-risk adenocarcinoma of the prostate <i>A. Quan, J. Ciezki, E. Klein, C. Reddy, K. Angermeier, J. Ulchaker, A. Mahadevan, G. DeOreo (U.S.A.)</i>	39
15:40	The impact of supplemental external beam radiation and/or androgen deprivation therapy on biochemical outcome following permanent prostate brachytherapy <i>D. Reed, G. Merrick, W. Butler, K. Wallner, R. Galbreath, J. Lief, Z. Allen, E. Adamovich (U.S.A.)</i>	40
15:50	Impact of hormone therapy on post implant dosimetry and outcome following I-125 implant monotherapy for localised prostate cancer <i>D. Ash, D. Bottomely, B. Al-Qaisieh, B. Carey, J. Joseph (United Kingdom)</i>	41
16:00	Dose escalation and toxicity limitation in prostate cancer therapy: conforming external beam treatment to dose delivered to prostate and critical adjacent normal structures by I-125 permanent implants <i>V. Narayana, S. Troyer, V. Evans, R. Winfield, P. Roberson, P. McLaughlin (U.S.A.)</i>	42
16:10	A retrospective comparison of the use of androgen deprivation among low and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy <i>J. Ciezki, E. Klein, K. Angermeier, J. Ulchaker, A. Mahadevan, C. Reddy (U.S.A.)</i>	43
16:20	Salvage treatment in local relapses after permanent prostate brachytherapy <i>J.J. Battermann (The Netherlands)</i>	44
16:30	Coffee	

FRIDAY 14 MAY

Proffered papers



Room B 14:30 - 16:30 Abstract N°

Miscellaneous: gynecology, rectum

moderator: B. Roth (Argentina)
 moderator: A. Biete Sola (Spain)
 moderator: K. Alektiar (USA)

- 14:30 Comparison of two low dose rates in vaginal prophylactic pre-operative brachytherapy for patients with stage I-II endometrial carcinoma : long-term results of a randomised trial 45
C. Haie-Meder, A. Kramar, H. El Boussairi, J. Bouzy, E. Briot, D. Castaigne (France)
- 14:40 Prophylactic vaginal high dose rate brachytherapy after pelvic irradiation in endometrial carcinoma 46
M. Carrascosa, M. Tortajada, J. Guinot, M. Aguayo, I. Beato, P. Escolar, J. Mengual, M. Casana, C. Pesudo, L. Arribas (Spain)
- 14:50 Post-operative external beam radiotherapy and vaginal cuff brachytherapy boost for endometrial cancer: survival rates, sites of failure and prognostic factors for recurrence 47
J. Fugazzi, I. Han, S. Lo, S. Keole, R. Patel, C. Zuniga, S. Tekyi-Mensah, A. Frazier (U.S.A.)
- 15:00 Prognostic factors on adjuvant radiotherapy of endometrial carcinoma: experience with external beam radiotherapy and high-dose rate brachytherapy 48
P. Novaes, M. Chen, I. Nishimoto, A. Pellizzon, R. Ferrigno, R. Fogaroli, M. Maia, J. Salvajoli (Brasil)
- 15:10 Adjuvant treatment with external radiotherapy and high-dose-rate brachytherapy in patients with endometrial tumours previously treated with surgery. Analysis of results and secondary effects 49
F. Casquero, M. Goicoechea, E. Boveda, O. Del Hoyo, B. Ruiz, J.M. Garcia, J.M. Espinosa, A. Loayza, F. Marcos, P. Bilbao (Spain)
- 15:20 Intravaginal HDR brachytherapy alone for intermediate risk endometrioid adenocarcinoma of the uterus 50
K. Alektiar, E. Venkatraman, D. Chi, R. Barakat (U.S.A.)



FRIDAY, 14 MAY

Proffered papers




FRIDAY
Proffered papers

Abstract N°

- | | | |
|-------|--|----|
| 15:30 | Predictors of treatment outcome after low dose rate temporary interstitial implantation for patients with locally advanced gynecologic malignancies
<i>J. Weidhaas, K. Alektiar, M. Zelefsky, R. Barakat, D. Chi (U.S.A.)</i> | 51 |
| 15:40 | Conservative treatment for vulvar cancer: chemoradiation and high dose rate brachytherapy
<i>M. Jolicoeur, T.V. Nguyen, S. David, A. Devieux, F. Goffin, P. Gauthier, P. Drouin, J. Dubuc, D. Provencher (Canada)</i> | 52 |
| 15:50 | Local control with interstitial brachytherapy implants in patients with carcinoma of the vagina
<i>W. Lamoreaux, M. Adli, I. Zoberi, P. Grigsby (U.S.A.)</i> | 53 |
| 16:00 | Consequences of brachytherapy (BT) on uterine myocontractility
<i>C. Haie-Meder, P. Morice, B. Paris, P. Duvillard, M.C. Vacher-Lavenue, R. de Crevoisier, T.M. Mignot, F. Ferré, M. Breuiller-Fouché (France)</i> | 54 |
| 16:10 | Sphincter preservation and brachytherapy for cancer of the rectum: updated results on 52 patients
<i>L. Grimard, H. Stern, M. Friedlich, J. Maroun, T. Moyana, J. Cygler (Canada)</i> | 55 |
| 16:20 | Factors influencing local failure and long-term outcomes among patients receiving high dose rate Iridium-192 intraoperative brachytherapy for colorectal adenocarcinoma
<i>W. Tereffe, M.J. Zelefsky, G.N. Cohen, K.M. Alektiar, M. Zaider, J. Guillem, P.B. Paty, M.R. Weiser, W.D. Wong, B.D. Minsky (U.S.A.)</i> | 56 |
| 16:30 | Coffee | |

FRIDAY 14 MAY

Symposia



Auditorium and Room B 17:00 - 18:30

Abstract N°

Brachytherapy in prostate cancer: HDR vs LDR

moderator: D. Ash (United Kingdom)
 moderator: P. Kasdorf (Uruguay)

17:00	Clinical confirmation that "HDR" monotherapy may be the best accelerated-hypofractionated treatment for prostate cancer <i>A. Martinez, C. Vargas, G.S. Gustafson, M. Hollander, H. Korman, I.S. Grills, M. Ghilezan, J. Gonzalez (U.S.A.)</i>	57
17:20	Combined external beam radiation and intensity modulated HDR-brachytherapy boost for localized prostate cancer <i>G. Kovacs (Germany)</i>	58
17:40	Brachytherapy as monotherapy in localised prostate cancer, permanent seed implantation or high dose rate? <i>J. Battermann (The Netherlands)</i>	59
18:00	Permanent seed implantation: the proven choice for your patient <i>D. Beyer (U.S.A.)</i>	60
18:20	Discussion	





SATURDAY 15 MAY

Symposium



Auditorium and Room B 08:00 - 09:50

Abstract N°

Accelerated partial breast irradiation

moderator: H. Marsiglia (France)
 moderator: O. Salazar (U.S.A.)

08:00	Interstitial brachytherapy for breast cancer: technical issues and avoiding pitfalls <i>R. Kuske (U.S.A.)</i>	61
08:20	Three year update of results with the MammoSite breast brachytherapy applicator <i>M. Keisch (U.S.A.)</i>	62
08:40	Mammosite: technical factors and outcome - European experience <i>C. Polgar, T. Major, P. Niehoff, G. Kovacs (Hungary)</i>	63
09:00	Accelerated partial breast irradiation (APBI): ready for prime time ? <i>T. Buchholz (U.S.A.)</i>	64
09:20	Accelerated partial breast irradiation (APBI): ready for prime time ? <i>Y. Belkacémi (France)</i>	65
09:40	Discussion	
09:50	Coffee	



SATURDAY 15 MAY

Proffered papers



Auditorium 10:20 - 11:35

Abstract N°

Prostate Cancer: dosimetry, economics

moderator: J.A. Polo Rubio (Spain)
 moderator: J. Speicht (USA)

10:20	3-dimensional MR spectroscopic imaging of prostate pre and post brachytherapy <i>J. Crook, A. Damyanovich, D. Taussky, A. Kirilova, A. Amirabadi (Canada)</i>	66
10:30	Biologic Image (MRSI) guided intraoperative computer optimized -directed dose escalation for transperineal permanent interstitial prostate implantation <i>N. Mathur, M. Zelefsky, Y. Yamada, H. Chan, G. Cohen, K. Zakian, M. Zaider (U.S.A.)</i>	67
10:40	Pre and post implant dosimetry for Iodine 125 prostate implant: comparison analysis <i>B. Al-Qaisieh, B. Carey, D. Ash, D. Bottomley, E. Brearley, A. Flynn (United Kingdom)</i>	68
10:50	Influence of postoperative dosimetric parameters on acute and chronic toxicity following peripheral loading brachytherapy with stranded iodine seeds <i>F. Kahmann, T.O. Henkel, P. Wust (Germany)</i>	69
11:00	Genito-urinary and gastro-intestinal toxicity after inverse planned permanent prostate implant with high activity seeds <i>B. Lebrun, F. Harel, L. Beaulieu, A.-G. Martin, J. Roy, É. Vigneault (Canada)</i>	70
11:10	Factors predicting for urinary incontinence following prostate brachytherapy <i>T. McElveen, F. Waterman, H. Kim, A. Dicker (U.S.A.)</i>	71
11:20	An economic evaluation of interstitial brachytherapy, radical prostatectomy and external beam radiotherapy for localized prostate cancer : results during the first year after therapy <i>C. Buron, L. Chauveinc, N. Salem, D. Peiffert, P. Pommier, M. Delannes, S. Guerif, A. Liwartovski, T. Flam, J. Cosset (France)</i>	72



SATURDAY 15 MAY

Proffered papers



Room B 10:20 - 11:35 Abstract N°

Breast Cancer

moderator: E. Van Limbergen (Belgium)
 moderator: J. Craven-Bartle Lamote (Spain)
 moderator: D. Arthur (USA)

10:20	T1 breast cancer tumors: results of breast-conserving therapy <i>C. Gutiérrez, A. Boladeras, J. Cacicedo, F. Moreno, V. Navarro, F. Guedea (Spain)</i>	73
10:30	Toxicity, local control and cosmesis after interstitial partial breast HDR Brachytherapy alone for T1/T2 Breast Cancer. <i>L. Berle, D. Wazer, R. Graham, M. Chung, J. Rothschild, T. Graves, B. Cady, T. DiPetrillo (U.S.A.)</i>	74
10:40	Second conservative treatment for early breast cancer: a non-randomized comparison with mastectomy <i>B. Guix, J.A. Lejarcegui, J.I. Tello, G. Zanon, H. Palombo, I. Henriquez (Spain)</i>	75
10:50	Accelerated partial breast irradiation with 192-iridium multicatheter PDR-/HDR-brachytherapy. 2-year results of the German-Austrian multicenter trial. <i>O.J. Ott, R. Pötter, J. Hammer, G. Hildebrandt, M. Lotter, A. Resch, M.W. Beckmann, R. Sauer, V. Strnad (Germany)</i>	76
11:00	Brachytherapy for accelerated partial breast irradiation: factors affecting toxicity and cosmesis <i>N. Shah, D. Arthur, T. Tenenholz, T. DiPetrillo, M. Rivard, G. Cardarelli, Z. Zheng, S. Kaufman, B. Bornstein, D. Wazer (U.S.A.)</i>	77
11:10	Is the breast post-operative seroma a reliable guide for planning accelerated partial breast irradiation? <i>H.A. Kader, M. Panades, P.T. Truong, W. Ansbacher, R. Pai, I.A. Olivotto (Canada)</i>	78
11:20	Dose-volume evaluation of HDR interstitial breast implants planned by traditional and image-based dosimetry systems <i>T. Major, C. Polgar, J. Fodor (Hungary)</i>	79

SATURDAY

Proffered papers

SATURDAY 15 MAY

Poster discussion



Auditorium 11:35 - 12:35

Abstract N°

Miscellaneous

moderator: E. Van Limbergen (Belgium)

Dosimetric comparisons between MammoSite HDR brachytherapy and conventional electron boost after external beam radiotherapy for early-stage breast cancer 80
A. Sadeghi, J. Lee, B. Prestidge, A. Rosenthal, L. Salinas, J. Hevezi (U.S.A.)

Design of a web page with the dosimetric parameters for all the different models of Cs-137 and Ir-192 sources used in brachytherapy 81
J. Pérez-Calatayud, F. Ballester, M. Lis, E. Casal, D. Granero, R. Cases, J. Venselaar (Spain)

Individualized vaginal moulds for LDR Iridium-192. Results in 55 patients 82
A. Roviroso (Spain)

Pulsed dose rate (PDR) intraoperative brachytherapy in soft tissue sarcomas : a retrospective study of 30 patients 83
L. Thomas, M. Delannes, E. Stoeckle, P. Martel, C. Llácer, M. Minsat, J. Bonnet, A. Chemin, N. Daly-Schweitzer, G. Kantor (France)

Squamous cell carcinoma of the lip and interstitial low dose rate brachytherapy (LDR). Evaluation of prognostic factors and estetic results. 84
J. Martínez-Galán, M. Martínez-Carrillo, A.B. Bezares-Alarcón, M. Zurita, R. Del Moral-Ávila, E. López-Ramírez, M. Navarro, V. Hernández (Spain)

PSA results after Iodine seed prostate brachytherapy in the UK with up to five years follow up 85
P. Sooriakumaran, A. Henderson, S.E.M. Langley, R.W. Laing (United Kingdom)

A prospective study of PSA bounce following iodine-125 brachytherapy in low risk prostate cancer 86
G. Morton, D. Loblaw, R. Choo, Y. Gray (Canada)

SATURDAY

Poster discussion

SATURDAY, 15 MAY

Poster discussion



Abstract N°

- Acute urinary retention following magnetic-resonance-
image-guided prostate brachytherapy 87
*D. Landis, D. Schultz, R. Cormack, C. Tempany, C. Beard,
 M. Hurwitz, K. Valentine, A. D'Amico (U.S.A.)*
- Influence of source strength on outcomes in patients undergoing
prostate I-125 seed implants for prostate carcinoma 88
*A. Mahadevan, C. Reddy, J. Ulchaker, K. Angermeier, T. Djemil,
 W. Wilkinson, J. Ciezki, E. Klein (U.S.A.)*
- Iodine-125 prostate brachytherapy in localized prostate cancer:
importance of team experience for dose delivery and toxicity 89
*S. Neubauer, P. Derakhshani, K. Muskalla, J. Metz, G. Spira
 (Germany)*
- Use of magnetic resonance imaging and spectroscopy to compare
the metabolic response of the prostate following external beam
radiation therapy and permanent prostate implants for early
stage prostate cancer 90
B. Pickett, J. Kurhanewicz, M. Roach (U.S.A.)
- Intraoperative real-time planning for HDR brachytherapy as
monotherapy in early stage prostate cancer 91
*T. Martin, D. Baltas, R. Kurek, S. Röddiger, T. Buhleier,
 U.W. Tunn, N. Zamboglou (Germany)*



SATURDAY 15 MAY

Proffered papers



Room B 11:35 - 12:35 Abstract N°

Physics: miscellaneous

moderator: T. Lahtinen (Finland)
 moderator: M.J. Rivard (USA)

11:35	A comparison between Paris, SSDS and target optimised dosimetry for interstitial brachytherapy breast boost <i>P. Ocampo, P. O'Reilly, P. Thirion, C. Kelly (Ireland)</i>	92
11:45	Can we rely on source holder correction factors given by the well chamber vendor? <i>P. Carrasco, N. Jornet, T. Eudaldo, M. Ribas (Spain)</i>	93
11:55	TLD dosimetry verification of dose optimisation method used in endovascular brachytherapy of peripheral vessels <i>G. Zwierzchowski, J. Skowronek (Poland)</i>	94
12:05	On-line implant reconstruction in HDR brachytherapy <i>I.K.K. Kolkman-Deurloo, W.J.M. de Kruijf, P.C. Levendag (The Netherlands)</i>	95
12:15	A method for checking HDR brachytherapy treatment plans <i>A. Wilkinson, E. Clouser, P. Fleming (U.S.A.)</i>	96
12:25	A novel beta particle silicon dosimeter <i>C. Cappellini, C. Bianchi, A. Bulgheroni, M. Caccia, L. Conte, E. Grigoriev, W. Kucwicz, A. Mozzanica, C. Sampietro (Italy)</i>	97
12:35	Lunch	

SATURDAY Proffered papers

SATURDAY, MAY 15

Symposium



Auditorium and B 14:30 - 16:30

Abstract N°

Time, dose, fractionation and radiobiology in the management of cervix cancer

moderator: B. Erickson (USA)
 moderator: B. Jones (United Kingdom)
 moderator: V. Bourel (Argentina)

14:30	LDR brachytherapy for carcinoma of the cervix <i>P. Eifel (U.S.A.)</i>	98
14:50	PDR brachytherapy in carcinoma for cervix <i>J.J. Mazon (France)</i>	99
15:10	Defining low/high dose rate as if biology mattered <i>M. Zaider (U.S.A.)</i>	100
15:30	The role of radiobiology in the management of cervix cancer <i>R. Dale (United Kingdom)</i>	101
15:50	Reporting time-dose pattern in intra-cavitary brachytherapy. Considerations on a common language using the linear quadratic model <i>R. Pötter, E. Van Limbergen, A. Wambersie (Austria, Belgium)</i>	102
16:30	Coffee	



SATURDAY 15 MAY

Proffered papers



Auditorium 17:00 - 19:00

Abstract N°

Prostate Cancer: side effects

moderator: N. Zamboglou (Germany)
 moderator: J. Cosset (France)
 moderator: J. Michalski (USA)

17:00	Prostate brachytherapy toxicity: Leeds experience <i>D. Bottomley, B. Al-Qaisieh, J. Joseph, D. Ash, B. Carey, S. St Clair (United Kingdom)</i>	103
17:10	Chronic toxicity profile and biochemical outcome in favorable-stage prostate cancer patients undergoing monotherapy with HDR or LDR (Pd103) brachytherapy at William Beaumont Hospital <i>M. Ghilezan, C. Vargas, G. Gustafson, L. Kestin, P. Chen, D. Brabbins, F. Vicini, E. Sebastian, G. Edmundson, A. Martinez (Italy)</i>	104
17:20	Analysis of acute and late morbidity, and biochemical control for intermediate to high risk prostate cancer treated with androgen deprivation, HDR and 3D/IMRT: 4 year results of a phase I-II dose escalation trial <i>A. Raben 1, A. Grebler 2, S. Sim 2, J. Geltzeiler, I. Keselman, S. Litvin, M. Geltzeiler, D. Raben, D. Crawford, J. Yang (U.S.A.)</i>	105
17:30	Outcome and quality of life after HDR brachytherapy in patients with high-risk localized prostate cancer <i>H. Zinkin, R. Roth, T. Lo (U.S.A.)</i>	106
17:40	Comprehensive quality of life comparison between high dose conformal radiotherapy and intraoperative-planned conformal brachytherapy for patients with localized prostate cancer <i>R. Nayak, M. Zelefsky, S. Leibel, Y. Yamada, P. Scardino, J. Eastham, H. Chen, H. Seo, R. Linehan, M. Kattan (U.S.A.)</i>	107
17:50	Effect of multiple variables on acute urinary morbidity following permanent I-125 implantation of the prostate: insights from a prospective, randomized trial <i>J. Ciezki, M. Elshaikh, T. Carlson, C. Reddy, E. Klein, K. Angermeier, J. Ulchaker (U.S.A.)</i>	108



SATURDAY, 15 MAY

Proffered papers



Abstract N°

18:00	<p>Early urinary morbidity after I125 transperineal interstitial permanent prostate brachytherapy. A multivariate analysis of 600 patients treated by the Institut Curie / Hopital Cochin/Hopital Necker Paris Group <i>L. Chauveinc, T. Flam, N. Thiounn, S. Solignac, M. Timbert, J. Rosenwald, P. Philips, F. Firmin, B. Debré, J. Cosset (France)</i></p>	109
18:10	<p>Influence of intraoperative prostate volume on early urinary toxicity after permanent prostate brachytherapy <i>P. Derakhshani, S. Neubauer, K. Muskalla, J. Metz, G. Spira (Germany)</i></p>	110
18:20	<p>Decreased incidence of urinary retention after prostate brachytherapy: the effect of learning curve? <i>D. Schellenberg, M. Keyes, J. Bucci, V. Moravan, W.J. Morris (Canada)</i></p>	111
18:30	<p>Erectile dysfunction (ED) after prostate cancer brachytherapy as sole treatment modality. The William Beaumont Hospital's experience with HDR vs. LDR (Pd103 permanent implants) <i>M. Ghilezan, C. Vargas, G. Gustafson, L. Kestin, P. Chen, D. Brabbins, F. Vicni, E. Sebastian, G. Edmundson, A. Martinez (Italy)</i></p>	112
18:40	<p>125-Iodine prostate brachytherapy and erectile dysfunction- Prospective UK data <i>A. Henderson, P. Sooriakumaran, S.E.M. Langley, R.W. Laing (United Kingdom)</i></p>	113
18:50	<p>Sexual function after permanent implant brachytherapy for prostate cancer : a multivariate analysis <i>L. Chauveinc, T. Flam, N. Thiounn, S. Solignac, M. Timbert, J. Rosenwald, N. Nebout, F. Firmin, B. Debré, J. Cosset (France)</i></p>	114



SATURDAY 15 MAY

Proffered papers



Room B 17:00 - 19:00 Abstract N°

Head and neck, Miscellaneous

moderator: D. Peiffert (France)
 moderator: A. Puthawala (USA)

17:00	Adjuvant HDR brachytherapy after external beam radiotherapy in 182 with nasopharyngeal cancer patients <i>E. Ozyar, G. Yazici, F. Yildiz, M. Cengiz, S. Gurdalli, F. Akyol, I.L. Atahan (Turkey)</i>	115
17:10	Combined external beam radiation therapy and HDR intracavitary brachytherapy boost in nasopharyngeal cancer: a retrospective analysis <i>N. Nguyen, R. Allbright, M. Drapeau, J. Hsiang, J. Wong, D. Nori (U.S.A.)</i>	116
17:20	High dose rate brachytherapy with stiff applicators in the treatment of nasopharyngeal lymphoepithelioma in childhood <i>P. Novaes, R. Nakamura, A. Pellizzon, R. Ferrigno, M. Maia, R. Fogaroli, J. Salvajoli, C. Antonelli, B. De Camargo (Brasil)</i>	117
17:30	Exclusive LDR brachytherapy in 279 patients with T2N0 tongue carcinoma <i>C. Bourgier, B. Coche-Dequeant, C. Fournier, B. Castelian, B. Prevost, T. Lacornerie, E. Castellanos, E. Lartigau (France)</i>	118
17:40	Long time experience of pulsed brachytherapy in base of tongue cancers <i>B. Johansson, J. Reizenstein, L. Karlsson (Sweden)</i>	119
17:50	Primary carcinoma of the oropharynx, relapse and complications: cost analysis comparing brachytherapy versus surgery <i>P. Levendag, W. Nijdam, I. Noever, C. Uyl-de Groot, M. van Agthoven (The Netherlands)</i>	120
18:00	High dose rate (HDR) interstitial brachytherapy for stage III and IV head and neck cancers <i>A. Puthawala, A. Syed, A. Sharma, J. Hepel (U.S.A.)</i>	121



SATURDAY, 15 MAY

Proffered papers



Abstract N°

18:10	First report of an institutional phase I-II trial of perioperative fractionated HDR brachytherapy (PHDRB) <i>R. Martínez-Monge, M. Cambeiro, C. Garrán, M. Jurado, J. Alcalde, M. San Julián, S. Amillo, C. Concejo, J. Hernández-Lizoain, F. Pardo (Spain)</i>	122
18:20	Low dose rate intraoperative brachytherapy in soft tissue sarcomas involving neurovascular structures <i>C. Liácer, M. Delannes, M. Minsat, E. Stoeckle, P. Martel, P. Bonneville, B.N. Bui, C. Chevreau, N. Daly-Schweitzer, L. Thomas (France)</i>	123
18:30	Brachytherapy for penile cancer: results for 49 patients <i>J. Crook, L. Grimard, B. Esche, J. Jezioranski, G. Pond (Canada)</i>	124
18:40	Gliosite radiotherapy system for treatment of recurrent malignant glioma: a multi-institutional analysis <i>A. Gabayan, A. Sanan, M. Lachaine, J. Woolfenden, B. Stea (U.S.A.)</i>	125
18:50	Endovascular Brachytherapy with 192 Iridium after Femoropopliteal-Stenting. Results from the Vienna-5 Trial <i>B. Pokrajac, R. Wolfram, A. Budinsky, R. Schmid, C. Kirisits, R. Poetter, E. Minar (Austria)</i>	126





Posters



Abstract N°

Breast Cancer

The dose volume relationship of lung and cardiac tissue in single source breast brachytherapy compared to external beam tangent fields for subclinical physiologic changes 127
R. Garza, K. Albuquerque, A. Sethi (U.S.A.)

HDR/PDR interstitial intensity modulated brachytherapy for local recurrences of the breast/thoracic wall following breast cancer 128
P. Niehoff, J. Dietrich, H. Ostertag, P. Kohr, B. Kimmig, G. Kovács (Germany)

Skin ellipse technique for Mammosite® device placement 129
J. Falk, K. Gerszten, D.E. Heron, R. Mogus, C.L. Rawlins, M. Bonaventura, R. Johnson, D. Keenan, J. Kelley (U.S.A.)

Long-term results of chest wall reirradiation using pulsed dose rate (PDR) brachytherapy moulds for breast cancer local recurrences 130
W. Harms, R. Krempien, C. Grehn, F. Hensley, C. Berns, J. Debus (Germany)

High dose rate brachytherapy in conservative treatment of breast cancer. An ambulatory method. Analysis of results 131
F. Casquero, M. Goicoechea, E. Boveda, O. Del Hoyo, B. Ruiz, J. Celeiro, R. Ortiz de Zarate, B. Usategui, F. Marcos, P. Bilbao (Spain)

A phase II randomised trial of partial breast irradiation for early stage breast cancer using the Mammosite® radiation therapy system vs conventional external beam radiotherapy (EBRT) 132
Z. Malik, C.D. Lee, A. Snee, A. SunMyint (United Kingdom)

Accelerated partial breast irradiation (APBI): are the current dose prescriptions for brachytherapy and 3D conformal external beam (3D-CRT) equivalent? 133
D.A. Todor, L.W. Cuttino, D.W. Arthur, R. George, L. Pacyna (U.S.A.)





Abstract N°

- Partial breast brachytherapy using multiple dwell positions in a single channel interstitial device - mammosite 134
A. Sharma, N. Syed, A. Puthawala (U.S.A.)
- Partial breast high dose rate (HDR) brachytherapy: a preliminary prospective study 135
B. Amendola, C. Lopez Penalver, M. Amendola, C. Lou (U.S.A.)
- Preliminary results of Pulsed Dose Rate peri-operative Brachytherapy (PDR BT) as an interstitial boost in conservative treatment (BCT) of breast cancer 136
K. Serkies, J. Jaskiewicz, Z. Tarnawska, J. Jassem (Poland)
- Single fraction boost with high dose rate brachytherapy in breast conserving therapy 137
L. Arribas, M. Aguayo, J.L. Guinot, M. Carrascosa, M. Tortajada, P. Escolar, J.L. Mengual, M.L. Chust (Spain)
- Conformal peroperative interstitial sole brachytherapy of early stage breast carcinoma using the HDR afterloading 138
R. Soumarova, H. Perkova, V. Chrenko, J. Zaloudik, P. Slampa, V. Fait, R. Bartlova, H. Ticha, J. Ruzickova (Czech Republic)
- A new methodology for quantitatively measuring conformance index of mammosite catheter implants 139
H. Zinkin, M. Rivard, Z. Zheng, T. DiPetrillo, D. Wazer (U.S.A.)
- Electronic (non-isotopic) high dose rate brachytherapy (EHDRB): design, characterization and pilot animal trial of a novel method of accelerated partial breast irradiation 140
J. Rieke, J. Williams, S. Hansen, T. Rusch, J. White (U.S.A.)
- High dose rate brachytherapy boost in breast-conserving surgery: skin-sparing and target determination 141
F. Piro, S. Abonante, L. Marafioti, M. Veltri, V. Oriolo (Italy)
- CT-based treatment planning in mammosite brachytherapy 142
F. Cattani, M. Ciocca, R. Lazzari, A. Vavassori, P. Canino, B. Ballardini, V. Piazza, R. Gennari, A. Costa, R. Orecchia (Italy)

POSTERS

Posters



Abstract N°

- Partial breast irradiation using mammosite RTS: preliminary results of a single institution phase II pilot study 143
Y. Belkacemi, M. Chauvet, S. Giard, T. Lacornerie, M. Castellanos, F. Bonodeau, M. Baranzelli, E. Lartigau (France)
- CT computer-optimized HDR surface applicator brachytherapy provides a more homogeneous scar boost dose than electrons following breast reconstruction 144
A.J. Stewart, D.A. O'Farrell, J. Kazakin, R.A. Cormack, M.A. Czerminska, J. Hansen, J.R. Bellon, P.M. Devlin (U.S.A.)



Posters



Abstract N°

Cervix Cancer

- Prognostic factor analysis in primary radiotherapy of cervical carcinoma 145
H.D. Weitmann, C. Czembirek, T.H. Knocke, R. Pötter (Austria)
- Carcinoma of the uterine cervix: moving from LDR to HDR 146
E. Rosenblatt, Z. Bernstein, A. Amit, E. Gez, A. Beny, K. Drumea, R. Bar-Deroma, A. Nevelsky, A. Berniger, A. Kuten (Israel)
- Comparison of dose volume histograms of 3-D brachytherapy planning for cervical cancer with empty and full bladder 147
M. Cengiz, S. Gurdalli, U. Selek, F. Yildiz, E. Ozyar, I.L. Atahan (Turkey)
- High (HDR) and low dose rates (LDR) brachytherapy (BT): comparison of side-effects and survival 148
E. Bakhshinyan, A. Khangel'dyan, R. Sulkhanyan (Armenia)
- MRI based treatment planning in cervical cancer brachytherapy : characteristics of the 2 cm³ volume receiving the highest dose in bladder and rectum walls, compared with ICRU reference points 149
T.V. Nguyen, I. Ddumas, P. Petrow, E. Briot, C. Petit, C. Haie-Meder (France)
- Interstitial brachytherapy (MUPIT) in gynecologic tumors: results and toxicity analysis 150
S. Rodriguez Villalba, M. Santos Ortega, N. Carballo, M. Llorente Manso, J. Martinez, L. Chiva, A. Ruiz Lopez (Spain)
- Combined MRI based intracavitary and interstitial brachytherapy for locally advanced cervical cancer with a modified tandem ring applicator – Design, quality assurance and dosimetry 151
S. Lang, J. Dimopoulos, C. Kirisits, N. Bauer, N. Wachter-Gerstner, S. Wachter, D. Georg, R. Pötter (Austria)

POSTERS

Posters



Abstract N°

- MRI-guided treatment planning for cervical cancer patients treated with a combination of external beam radiotherapy and PDR-brachytherapy 152
L. van de Bunt, I.M. Jürgenliemk-Schulz, U.A. Heide van der, G.A.P. Kort de, C. Ceylan, M. Ketelaars, J.J. Battermann (The Netherlands)
- A simple method to minimize critical structure irradiation based on analysis of inter-fractional geometric variation in the course of vaginal cuff brachytherapy 153
Z. Symon, J. Menhel, D. Alezra, L. Tsvang, D. Levin, R. Catane, R. Pfeffer (Israel)
- Experience with high-dose-rate brachytherapy (HDR) in carcinoma uterine cervix in the department of Radiation Oncology of Hospital Carlos Haya in Malaga (Spain) 154
I. Garcia Rios, I. Heruzzo, J.M. Azcoaga, J. Contreras, J. Macias, D. Rivas, I. Fortes, A. Wals, R. Delgado, C. Bodineau, I. Jerez (Spain)
- Anxiety and depression in gynecologic cancer patients before, during and after brachytherapy. A randomized study 155
C. Leon, A. Rovirosa, F. Casas, B. Farrús, I. Gic, A. Biete, J. Craven-Bartle, J. Sierra, A. Arcusa (Spain)
- Magnetic resonance evaluation based modifications of standard brachytherapy technique in cervical cancer treatment 156
J. Hadjiev, G. Antal, A. Benko, P. Bogner, Z. Cselik, I. Repa (Hungary)
- Increasing the dose rate of medium dose rate brachytherapy in the definitive radiation treatment of advanced cervical carcinoma: impact on local control and late complications 157
O.F. Coza, C. Ordeanu, S. Gavris, D. Suciú (Romania)
- One or two MDR-brachytherapy fractions in the treatment of locally advanced cervical carcinoma 158
C. Ordeanu, O. Coza, S. Gavris, D. Suciú (Romania)



Posters



Abstract N°

- Medium and high dose rate brachytherapy for cervix cancer :
experience of study group - Brazilian institutions 159
*M.J. Alves, G. Menegussi, E.L. Pessoa, P.E.R.S. Novaes,
A.C.P. Pellizzon, J.V. Salvajoli (Brasil)*
- Results of cervical carcinoma treated with external
Radiotherapy and High Dose Rate Brachytherapy 160
*M. Jorge Lemos, M. Ortiz Monterrey, O. Condon,
I. Monteiro Grillo (Portugal)*
- Preoperative concurrent radiotherapy and chemotherapy in
uterine cervix cancer 161
*L. Kochbati, C. Nasr Ben Ammar, F. Benna, H. Frikha,
W. Gargouri, M. Besbes, K. Rahal, K. Ben Romdhane,
F. Ben Ayed, M. Maalej (Tunisia)*
- First results of chemoradiation in cervical cancers with high
dose rate brachytherapy combined with external beam
radiotherapy 162
G. Haensgen, H. Strauss, T. Kuhnt, J. Dunst (Germany)
- Positional stability of Töre's applicator and dose variations
with time during LDR brachytherapy for cervical carcinoma 163
*S. Kucucuk, M. Okutan, G. Kemikler, R. Alas, I. Aslay, G. Töre
(Turkey)*
- Remote afterloading for HDR neutron brachytherapy with
Californium-252 164
T. Tacev, T. Papirek, V. Kolarik (Czech Republic)
- CT based dose distribution and optimization for gynecological
pulsed dose rate interstitial brachytherapy 165
*C. Brunaud, F. Ahmad, D. Peiffert, Y. Metayer, P. Aletti
(France)*
- A pilot phase II trial with Cisplatin - Paclitaxel treatment
and concurrent external and endocavitary radiotherapy in
locally advanced cervical cancer 166
*P. Franzone, L. Miglietta, L. Tacchini, F. Foppiano,
M. Bruzzone, T. Scolaro, F. Giannelli, M. Ferrarini, V. Vitale
(Italy)*

POSTERS

Posters



Abstract N°

- | | |
|--|------------|
| <p>Carcinoma of the uterine cervix: a single institution experience using PDR brachytherapy in 125 consecutive patients
 <i>B. Castelain, O. Olszyk, E. Leblanc, L. Poupon, A. Chevallier, F. Narducci, S. Taieb, E. Lartigau, Y. Belkacemi (France)</i></p> | <p>167</p> |
| <p>Brachytherapy of adenocarcinoma of cervix uteri and endometrial adenocarcinoma
 <i>L. Krikunova, N. Shentereva, L. Mkrtchyan, K. Salmanova (Russian Federat)</i></p> | <p>168</p> |
| <p>Brachytherapy of the uterine cervix using 60Co-HDR and 137Cs-MDR
 <i>M. Kiseleva, L. Krikunova (Russian Federat)</i></p> | <p>169</p> |
| <p>Cervical cancer: experience in the Department of Radiation Oncology. H.U. "Reina Sofia" Cordoba
 <i>S. Garcia, A. Béjar, A. Palacios, L. Tudela, E. Munoz, M. Rodriguez, M. Espinosa, J.L. Romeo, M.D. Lopez (Spain)</i></p> | <p>170</p> |
| <p>Intracavitary brachytherapy for endometrial cancer. Experience in the Department of Radiation Oncology. H.U. "Reina Sofia", Cordoba
 <i>S. Garcia, A. Béjar, A. Palacios, E. Munoz, L. Tudela, M. Rodriguez, M. Espinosa, M.D. Lopez, J.L. Romeo</i></p> | <p>171</p> |



Posters



Abstract N°

Physics

- Evaluation of technical failures during treatment in pulsed dose rate brachytherapy 172
K. Koedoodeer, R. Tiggelaar, J. van der Grient, N. van Wieringen, G. D'Oliesslager, L. Blank, B. Pieters (The Netherlands)
- Phantom size in brachytherapy source dosimetric studies 173
F. Ballester, D. Granero, J. Pérez-Calatayud, E. Casal, V. Puchades, R. Cases (Spain)
- Practising the LD dosimetry concept for permanent prostatic seed implants 174
A. van 't Riet, C. Hoekstra, J. Immerzeel, L. Elders, R. Westendorp, F. Ypma (The Netherlands)
- The BCCA's HDR breast brachytherapy program - A physicist's view 175
W. Ansbacher, C.C. Popescu, M. Panades, P.T. Truong, H.A. Kader (Canada)
- Development of a field-customizable neural network nomogram equivalent 176
D.A. Silvern, C.R. Moorthy (Israel)
- Percent depth dose for a sphere of 32p chromic phosphorous colloid 177
C. Hechtman, Z. Li, D. Mansur, P. Grigsby (U.S.A.)
- Radiation safety after permanent prostate brachytherapy 178
F. Cattani, A. Polo, A. Vavassori, M. Severgnini, E. Rondi, C. Garibaldi, R. Cambria, O. Orecchia, G. Tosi (Italy)
- Protecting the urethra in prostate HDR brachytherapy: the template geometry does matter 179
L. Beaulieu, C. Tremblay, É. Lessard, J. Pouliot, B. Lachance, É. Vigneault (Canada)
- Silicon detector versus gafchromic film for brachytherapy sources characterisation 180
C. Bianchi, M. Caccia, C. Cappellini, L. Conte, E. Grigoriev, R. Lorusso, R. Novario, C. Sampietro, F. Tanzi (Italy)

POSTERS

Posters



Abstract N°

- Application of the TG-43 dosimetry protocol to electronic brachytherapy sources 181
T. Rusch, M. Rivard (U.S.A.)
- Dosimetric study of the 15 mm ropes eye plaque 182
F. Ballester, D. Granero, J. Pérez-Calatayud, E. Casal, V. Puchades, R. Cases (Spain)
- Dose response of gafchromic XR-T film to a new electronic brachytherapy source 183
S. Chiu-Tsao, T. Rusch, S. Axelrod, H. Tsao, L. Harrison (U.S.A.)
- The angular homogeneity index, a tool for greater precision and accuracy in the assessment of homogeneity 184
P. Ocampo, C. Kelly (Ireland)
- A fractionated brachytherapy mold technique can replace IMRT for treatment of a complex shallow target 185
Y. Pipman, H. Gaballa, E. Obedian (U.S.A.)
- Bouquet brachytherapy: the feasibility and optimization of conically spaced implants 186
F. Lei, W.S. Ng, H. Liu, W. O'Dell, D. Rubens, Y. Yu (U.S.A.)
- Quality Assurance of Treatment Planning System (TPS) in Low Dose Rate Brachytherapy (LDR) using Thermoluminescence Dosimetry (LiF) 187
M. Besbes, S. Abdessaied, L. Kochbati, H. Frikha, W. Gargourdi, C. Nasr Ben Ammar, F. Benna, M. Maalej (Tunisia)
- Quality assurance of a high dose rate afterloader 188
S. Gysbrechts, J. Camps, M.J. Martens, L. Noé, J. Meyskens, J.A. Rutten (Belgium)
- The impact of number of the Norman Simon (NS) applicators on dose distribution in endometrial cancer patients treated with pulsed dose rate brachytherapy (PDR BT). 189
Z. Tarnawska, K. Serkies, J. Jassem (Poland)



Posters



Abstract N°

32P endovascular brachytherapy source experimental dosimetry 190
*A. Fidanzio, F. Perrone, L. Azario, L. Grimaldi, R. Capote,
A. Piermattei (Italy)*

Experience associated with the verification of the reference
air kerma rate of I-125 seeds 191
*M.C. Baños, J. Bea, L. Larrea, M.A. García, E. López, C. Pla
(Spain)*

Three dimensional dose distribution in pulsed dose rate
oropharyngeal brachytherapy : comparison of 3 methods : non
optimization, dose point optimization and inverse optimization 192
*F. Ahmad, M. Lapeyre, S. Forestier, C. Brunaud, P. Aletti,
V. Marchesi, D. Peiffert, S. Hoffstetter, A. Noël (France)*

POSTERS

Posters



Abstract N°

Prostate cancer

- The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer 193
D. Ash, B. Al-Qaisieh, J. Joseph, D. Bottomley, B. Carey (United Kingdom)
- Enzymatic prostatic acid phosphatase in the clinical staging of patients with newly diagnosed, untreated prostate cancer 194
D. Reed, G. Merrick, W. Butler, K. Wallner, Z. Allen, J. DeFilippo, E. Adamovich (U.S.A.)
- The impact of prostate volume and neoadjuvant androgen deprivation therapy on urinary function following prostate brachytherapy 195
D. Reed, G. Merrick, W. Butler, K. Wallner, Z. Allen, J. Lief, A. Hinerman-Mulroy, R. Galbreath (U.S.A.)
- Simplified data analysis with a relational database dedicated to prostate brachytherapy 196
L. Astrom (Norway)
- Intermediate results of ferromagnetic thermal ablation for radiation failure local recurrence of prostate cancer 197
K. Shinohara, V. Master, P. Carroll, D. McLeod, D. Beyer (U.S.A.)
- Permanent I-125 prostatic seed implantation technique in a University Hospital. Preliminary results 198
I. Herruzo Cabrera, C. Bodineau, P. Galan, F. Diaz, P. Rodero, J. Azcoaga, I. Garcia-Rios, A. Villanueva, J. Macias, I. Jerez, J. Contreras (Spain)
- Brachytherapy in confined prostate cancer treated with I 125, experience in Mexico 199
A. Pamanes-Ochoa, J. Suarez-Campos, L. Guzman-Ruiz, B. Castillo-Lopez (Mexico)
- PSA bounce after transperineal iodine prostate brachytherapy 200
N. Salem, F. Bladou, G. Gravis, M. Simonian, G. Serment (France)



Posters



Abstract N°

- Conformance of the seedselectron to manufacturer specifications and ABS/AAPM recommendations 201
M. Rivard, D. Evans, I. Kay (U.S.A.)
- Prostate HDR brachytherapy. An outpatient approach 202
A. Korba, T. Gadiant, P. Gilson, A. Razek, B. Romick, W. Samm, S. Shah, P. Siami, B. Smith, A. Sorensen (U.S.A.)
- A newly available radio-isotope with dosimetric and biologic advantages for the treatment of prostate cancer 203
L. Korb, M. Phillips (U.S.A.)
- Comparison of CT and ultrasound based treatment planning for treatment of prostate gland using high dose rate (HDR) brachytherapy 204
M. Mirzaei, W.R. Lee, K.E. Ekstrand (U.S.A.)
- Factors predicting an increased dose to the penile bulb in permanent seed prostate brachytherapy 205
D. Taussky, M. Haider, M. McLean, I. Yeung, T. Williams, S. Pearson, G. Lockwood, J. Crook (Canada)
- Measurement of urethral dose profiles in prostate brachytherapy using a linear Mosfet array dosimeter 206
J.E. Cygler, A. Saoudi, G. Perry, A. Hallil, M. Brown, I. Thomson (Canada)
- The benefits provided by using intra-operative dosimetry and the fusion of MRI to CT for post plan dosimetry in the learning curve of transperineal interstitial permanent prostate brachytherapy 207
I. Aslay, G. Kemikler, N. Tenekeci, I. Ozbay, M. Akinci (Turkey)
- Efficiency of manual and automatic seed delivery in permanent prostate implants 208
M.J.H. Van Deursen, R.I. Schokker, M.A. Moerland, J.J. Battermann (The Netherlands)
- The use of fiducial markers for verification of catheter position in HDR prostate brachytherapy 209
G. Perry, D. Wilkins, J. Cygler, A. Saoudi, C. Morash (Canada)

POSTERS

Posters



Abstract N°

- HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation for unfavorable stage prostate cancer 210
R. Kurek, T. Martin, S. Röddiger, T. Dannenberg, B. Rogge, D. Baltas, U. Tunn, N. Zamboglou (Germany)
- The impact of intra-operative delivery accuracy on intra-operative and post-operative dosimetry for prostate treatments using a low dose-rate iodine-125 remote afterloader 211
S. Husain, D. Evans, S. Angyalfi, I. Kay, K. Breitman, P. Dunscombe (Canada)
- Comparison of dose distribution at the intraprostatic urethra based on interactive dynamic real-time TRUS and CT after permanent seed implantation 212
G. Maurer, U. Maurer, F. Bialas, K. Lang, J. Zumbe (Germany)
- Real time prostate implant with rapid strand I125 seeds. The experience with 43 patients treated in 2003. 213
M. Feijóo, L. Pinto, F. Vaz, R. Múglia, G. Magela (Brasil)
- Mixed stranded and free I-125 sources for permanent prostate implant 214
R. Burette, A. Corbusier, P. Devlesaver, F. Germeau, J. Vanderick, P. Warnier (Belgium)
- First results of brachytherapy for prostate cancer with J-125-seeds using the Nucletron first™ system 215
M. Niewald, N. Licht, T. Loch, J. Fleckenstein, L. Wisser, C. Rube (Germany)
- Prevention of prostate HDR needle dislocation using the brachybench, a secure, comfortable, "air-ride", patient positioning and transfer device 216
T.J. Tidwell (U.S.A.)
- Clinical outcome of patients with prostate cancer treated with external beam radiation and iridium sources 217
K.M. Kalkner, M. Haggman, M. Edgren, B. Lennernas, G. Bohlin, P.-O. Sjoden, P. Strang, R. Zimmerman, G. Sahlen, S. Nilsson (Sweden)



Posters



Abstract N°

- Prostate brachytherapy with 125 I. Results of 45 patients treated at the Hospital de la Santa Creu i Sant Pau. Can dosimetric parameters predict the clinical outcome? 218
G. Sancho, P. Carrasco, N. Jornet, M. Bonet, I. Membrive, T. Eudaldo, G. Gómez de Segura, M. Ribas, J. Craven-Bartle (Spain)
- MRI-Guided HDR prostate brachytherapy in a Standard 1.5T Scanner 219
D. Citrin, R. Susil, G. Gustafson, H. Ning, R. Miller, E. Lessard, J. Pouliot, C. Coleman, K. Camphausen, C. Menard (U.S.A.)
- Improved patient education for prostate brachytherapy using web-based picturing diagrams for graphical representation of data 220
A. Abner, G. Maathowitz, P. Meskill, E. Holupka (U.S.A.)
- What percent of seeds need to be detected for effective intraoperative dosimetry during permanent prostate brachytherapy? 221
Y. Su, B. Davis, M. Herman, R. Robb (U.S.A.)
- Combined ultrasound-radiographic approach to the intraoperative detection of seeds in prostate brachytherapy: a feasibility study 222
G.N. Cohen, V.A. Dumane, M. Zaider, M.F. Worman (U.S.A.)
- Intraoperative brachytherapy technique of low dose rate with 125I in real time and by dynamic calculation 223
P. Prada, G. Juan, J. Fernandez, J. Gonzalez (Spain)
- Comparison of virtual and live plans in -real time- brachytherapy in prostate cancer based on ultrasound examination 224
J. Bystrzycka, B. Bialas, K. Slosarek, M. Fijalkowski (Poland)
- Conformity error: a new method for evaluating the conformity of interstitial brachytherapy implants 225
D. Kelly (U.S.A.)
- Iodine 125 brachytherapy for prostate cancer in Ravenna (Italy) 226
M. Del Duca, S. Palazzi, E. Emiliani, M. Giannini, C. Dal Pozzo, C. Di Stefano, G. Severini, G. Gnani, G. Mazzotti, M. Morelli (Italy)

POSTERS

Posters



Abstract N°

- Assessment of pain and its contributing factors during HDR prostate brachytherapy 227
G. Gejerman, J. Colella, S. Scrofine, E. Bagiella, J. Scheuch, V. Lanteri, A. Siegel, S. Levey, R. Watson, I. Sawczuk (U.S.A.)
- Permanent J-125 brachytherapy of localized prostate cancer – Quality of life and local control 228
P.M. Messer, H.-W. Gottfried, H. Alfia, N.M. Blumstein, E. Schneider, R.E. Hautmann, E.M. Röttinger (Germany)
- Deciding on a treatment for prostate cancer: how and why men choose high dose rate (HDR) brachytherapy 229
D. Kelly (U.S.A.)
- Variation regarding the calibration certificate and uncertainties in the calibration of air-kerma strength reference (AKSR) of Amersham 6711 Iodine-125 seeds 230
V. Luna, J.M. Gonzalez, J. Fernandez, D. Crelgo, A. Rodriguez, P. Sanchez, J. Vivanco (Spain)
- First experiences with dynamic interactive realtime dose verification during transperineal permanent seed implantation (TPSI) of patients with "low risk" prostate cancer in an out-patient setting 231
T. Block, F. Zimmermann, H. Czempiel (Germany)
- Catheter reconstruction in TRUS-guided interstitial prostate HDR-brachytherapy under realtime-guidance with the planning system "Swift" 232
G. Spira, J. Metz, K. Muskalla, P. Derakhshani, S. Neubauer (Germany)
- A comparison of seed coordinates between CT based postplanning and a software based guidance system for inreoperative dosimetry during prostate seed implants 233
M. Razzag, E.C. Burdette, P.M. Meskell, E.J. Holupka (U.S.A.)
- Urinary function after prostate brachytherapy with rapid-strand 125-I in low-risk prostate cancer 234
B. Guix, R. Serrate, J.M. Bartrina, J.I. Tello, I. Henriquez, J.R. Vendrell, F. Finestres (Spain)



Posters



Abstract N°

- Anatomy-based inverse planning dose optimization for HDR prostate implant boost: a toxicity report 235
A. Mamouhdieh, L. Beaulieu, C. Tremblay, B. Lachance, A. Létourneau, É. Lessard, J. Pouliot, É. Vigneault (Canada)
- The applicability of simultaneous CT-US imaging for the evaluation of prostate implants 236
M.J. Steggerda, H.G. van der Poel, L.M.F. Moonen, L.J. Zijp, M. Herk van, C.J. Schneider (The Netherlands)
- Urethral geometric sparing factor for HDR prostate brachytherapy 237
G. Ingram, D. Kelly (U.S.A.)
- TRUS- and CT-"image fusion" in the postplanning procedure after transperineal permanent interstitial seedimplantation (TPSI) of "low risk" prostate cancer 238
T. Block, F. Zimmermann, H. Czempel (Germany)
- Combined 3-dimensional conformal radiotherapy and interstitial permanent implant for patients with intermediate and unfavorable risk prostate cancer 239
S. Yajnik, Y. Yamada, M.J. Zelefsky (U.S.A.)
- Extending protection of organ at risk to the bulb of the penis yields conformal treatment plans and lower D70% and D50% bulb doses with inverse planned simulated annealing (IPSA) high dose rate (HDR) brachytherapy 240
J.L. Speight, E. Lessard, I.C. Hsu, J. Pouliot (U.S.A.)
- Quality assurance for fractionated high dose rate afterloading brachytherapy as monotherapy for prostate cancer 241
P. Bownes, P.J. Hoskin, P.J. Ostler, G.J. Lowe, L. Bryant (United Kingdom)
- Image-fusion based CT pre and post-implant in seed implantation: a useful tool for accurate prostate definition in the post-planning setting. 242
A. Hervás, R. Moris, A. Montero, I. Rodriguez, S. Sancho, J. Delgado, R. Morera, M. Bejarano, A. Capuz, A. Ramos (Spain)



Posters



Abstract N°

- Combination of high dose rate brachytherapy boost and adjuvant hormonal therapy for prostate cancer
I. Hsu (U.S.A.) 243
- Dosimetry of high dose rate (HDR) brachytherapy is highly reliable
G. Ingram, D. Kelly, J. Flynn, W. Brookover, B. Kramer (U.S.A.) 244
- Does anaesthesia method impact implant-induced swelling of the prostate?
J. Aronowitz, J. Follette (U.S.A.) 245
- Brachytherapy of prostate cancer in patients with prior colorectal cancer
P.G. Koutrouvelis, S. Katz, N. Lailas, D. Theodorescu (U.S.A.) 246
- Detection of local recurrence after J-125 permanent brachytherapy of the prostate by 11C-Cholin-PET-CT and consequences for therapy
P.M. Messer, H.-W. Gottfried, N.M. Blumstein, E. Schneider, E.M. Röttinger (Germany) 247
- Permanent prostate gland seed implant: a comparison of dosimetry outcome between loose-seeds and rapid strand brachytherapy techniques
M. Fagundes, L. Nied, C. Sa Brito, W. Cavanagh, L. Fagundes (Brasil) 248
- Quality assurance in HDR brachytherapy for prostate cancer: how can prostate displacement be minimized?
B. Guix, J.M. Bartrina, R. Serrate, J.I. Tello, J.R. Vendrell, I. Henriquez (Spain) 249
- Permanent prostate brachytherapy as a second curative treatment in patients with local recurrences following external irradiation
D.J. Perry, J.D. Forman, M.L. Cher, A.J. Frazier, E. Arterbery, M. Yudelev (U.S.A.) 250
- Prospective evaluation of urinary morbidity following permanent interstitial brachytherapy for localized prostate cancer
M. Thoulouzan, M. Delannes, M. Soulié, P. Seguin, E. Huyghe, F. Jonca, R. Aziza, J. Bonnet, P. Plante, J.M. Bachaud (France) 251



Posters



Abstract N°

- Coverage of extra-capsular extension (ECE) with three dimensional conformal external beam radiotherapy (3DCRT) or permanent prostate seed implantation (PPI) 252
J. Andrews, B. Pickett, M. Roach (U.S.A.)
- Introduction of the seed selectron for automatic seed delivery in permanent prostate implants 253
M.A. Moerland, M.P.R. Van Gellekom, H.K. Wijrdeman, I. Schulz, J.J. Battermann (The Netherlands)
- Reliability of CT-based postimplant dose values in interstitial permanent brachytherapy 254
M. Pinkawa, B. Gagel, R. Holy, H. Borchers, G. Jakse, M.J. Eble (Germany)
- Salvage combined intensity modulated HDR brachytherapy and external beam treatment (EBRT) for local recurrences after radical prostatectomy: first results of a prospective feasibility and dose escalation study 255
P. Niehoff, G. Kovács, N. Nürnberg, T. Loch, R. Galalae, J. Egberts, B. Kimmig (Germany)
- Does cigarette smoking influence biochemical outcome following permanent prostate brachytherapy? 257
D. Reed, G. Merrick, W. Butler, K. Wallner, R. Galbreath, J. Lief, E. Adamovich (U.S.A.)
- Combined surgery and brachytherapy for lymph node negative bladder carcinoma 258
A. Ammor, R. De Crevoisier, B. Court, P. Wibault, E. Chirat, K. Fizaki, C. Theodore, C. Haie-Meder (France)
- The impact of anatomic challenges on HDR dosimetry and implant toxicity 259
G. Gejerman, A. Kapulsky, I. Rebo, A. Ndolvu, J. Napoli, J. Barbieri, I. Sawczuk, J. Hanley (U.S.A.)

POSTERS

Posters



Abstract N°

- Comparison of perioperative morbidity and acute toxicity in prostate HDR brachytherapy with permanent seed implants 260
G. Gejerman, S. Scrofine, J. Colella, E. Bagiella, E. Mullokandov, I. Rebo, A. Kapulsky, A. Ndolvu, J. Napoli, I. Sawczuk (U.S.A.)
- Androgen deprivation therapy in the management of patients with prostate volumes too large for radioactive seed implantation 261
R. Patel, J. Maier, D. Perry, M. Cher, C. Maitland, S. Rosemberg, M. Yudelev, C. Zuniga, A. Frazier (U.S.A.)
- Quality of dose distribution with realtime-plan-modification (RPM) in permanent seed implants 262
P. Derakhshani, S. Neubauer, K. Muskalla, J. Metz, G. Spira (Germany)
- HDR-afterloading in locally advanced prostate cancer in an outpatient setting - experience of an interdisciplinary prostate center 263
G. Spira, J. Metz, K. Muskalla, P. Derakhshani, S. Neubauer (Germany)
- Quality of implant dosimetry for intraoperative versus preoperative planning for permanent prostate seed implants: are there differences in coverage of the base, mid-zone and apex of the prostate? 264
D. Prasad, M. Lippert, D. Theodorescu, B. Schneider (U.S.A.)
- The influence of low dose regions on D90 values in permanent prostate implants 265
M. Van Gellekom, M. Moerland, H. Wijrdeman, I. Jurgenliemk-Schulz, J. Battermann (The Netherlands)
- Improved dosimetry by the use of a unique interactive image registered intra- operative treatment planning system for permanent seed brachytherapy 266
S. Doggett, E. Burdette (U.S.A.)



Posters



Abstract N°

- Clinical benefits of a class solution for inversely planned HDR prostate brachytherapy 267
E. Lessard, I.C. Hsu, J. Speight, E. Vigneault, B. Lachance, L. Beaulieu, C. Ménard, H. Ning, J. Pouliot (U.S.A.)
- 125 I RAPIDStrand Transperineal TRUS-Guided Prostate Brachytherapy: a prospective comparison of low versus high activity courses 268
H. Fagundes, R. Keys, M. Wojick, M. Radden, C. Bertelsman, W. Cavanagh (U.S.A.)
- Dose-effect relationship for grade-2 urethral toxicity in permanent prostate implants 269
G.N. Cohen, M. Zaider, L. Ben-Porat, M.J. Zelefsky (U.S.A.)
- Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/ml 270
D. Reed, G. Merrick, W. Butler, K. Wallner, R. Galbreath, E. Adamovich (U.S.A.)
- Number of catheters in prostate high dose rate brachytherapy: the role of inverse planning 271
J. Pouliot, E. Stickney, C. Charra-Brunaud, E. Lessard, V. Weinberg, I.C. Hsu (U.S.A.)
- Biochemical control and tolerance of HDR brachytherapy and 3-dimensional conformal radiotherapy for patients with clinically localized prostate cancer 272
S.K. Bhatia, J. Yamada, G.N. Cohen, M. Zaider, M.J. Zelefsky (U.S.A.)
- A MRI based treatment planning concept for interstitial HDR prostate treatments – Part II: dose and volume parameters 273
C. Kirisits, S. Wachter, S. Lang, D. Georg, R. Pötter (Austria)
- Minimal displacement of self-anchoring brachytherapy catheters in temporary prostate implants 274
B. Pieters, L. Blank, G. D'Olieslager, H. van der Grient, C. Koedooder, T. de Reijke (The Netherlands)



Posters



Abstract N°

- Urinary toxicity when using high dose rate prostate brachytherapy as a boost to conventional external beam radiation therapy in localized prostate cancer 275
A.C. Pellizzon, J. Salvajoli, P. Novaes, M. Maia, R. Fogaroli, R. Ferrigno, R. Pellizzon (Brasil)
- Quality of life after prostate brachytherapy: a prospective study 276
C. Hennequin, R. Thuret, F. Desgrandchamps, S. Michaud, P. Teillac, C. Maylin (France)
- The role of prophylactic tamsulosin(Flomax®) ± dexamethasone in patients undergoing prostate 125I seed implants for prostate carcinoma. A randomized double blind study 277
T. Carlson, J. Ciezki, D. Khuntia, M. Elshaikh, A. Mahadevan, C. Reddy, J. Ulchaker, K. Angermeier, E. Klein (U.S.A.)
- Targeting dominant intraprostatic lesion using functional imaging with MR spectroscopy and high dose rate brachytherapy 278
J. Pouliot, Y. Kim, E. Lessard, I.C. Hsu, D.B. Vigneron, J. Kurhanewicz (U.S.A.)
- Health related quality of life in low to high-risk prostate cancer patients treated by brachytherapy and 3D conformal radiotherapy 279
B. Guix, T.M. Lacorte, J.I. Tello, R. Serrate, J.M. Bartrina, J.R. Vendrell, I. Henriquez (Spain)
- 125I RAPIDStrand versus 103Pd for localized prostate cancer: a dosimetric analysis 280
H. Fagundes, R. Keys, M. Wojick, M. Radden, C. Bertelsman, W. Cavanagh (U.S.A.)
- Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation 281
D. Reed, G. Merrick, W. Butler, K. Wallner, R. Galbreath, Z. Allen, E. Adamovich (U.S.A.)



Posters



Abstract N°

- Chronic fatigue after permanent interstitial I-125-brachytherapy, temporary interstitial Ir-192-brachytherapy and external beam radiotherapy for prostate cancer 282
M. Pinkawa, K. Fishedick, B. Asadpour, B. Krenkel, R. Holy, Y. Kaplan, H. Borchers, G. Jakse, M.J. Eble (Germany)
- Dose-volume-time-impact on toxicity in interstitial temporary HDR-Ir-192-brachytherapy (BT) for prostate cancer 283
M. Pinkawa, K. Fishedick, H. Treusacher, G. Demirel, R. Mager, H. Borchers, G. Jakse, M.J. Eble (Germany)
- A MRI based treatment concept for interstitial HDR prostate treatments – Part I: clinical feasibility 285
S. Wachter, C. Kirisits, S. Lang, D. Georg (Austria)
- Organ contouring in permanent prostate brachytherapy (PPB) post-implant evaluation: a multicentric study 286
N. Di Muzio, P. Lavagnini, G. Fellin, A. Vavassori, D. Del Duca, P. Mangili, B. Longobardi (Italy)
- I-125 isodose patterns as predictors of inadequate prostate brachytherapy dose coverage 287
D. Reed, K. Wallner, P. Cho, E. Ford, G. Merrick (U.S.A.)
- A comparison of permanent brachytherapy (BT) and 3D conformal radiation therapy (3DCRT) for localized prostate cancer 288
J. Michalski, D. Mansur, J. Escobar, M. Lockett, C. Perez (U.S.A.)
- 192Ir LDR Brachytherapy (BT) is at least as efficient as HDR options for boosting intermediate or unfavourable prostate cancers after EBRT. Experience on 201 patients 289
P. Nickers, N. Jansen, B. Thissen, J.M. Deneufbourg (Belgium)
- Comparison of race and prostate cancer outcome in patients treated with brachytherapy 290
M. Kollmeier, J. Cesaretti, D. Huang, N. Stone, R. Stock (U.S.A.)

POSTERS

Posters



Abstract N°

- Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: an early Canadian experience 291
É. Vigneault, A.-G. Martin, L. Beaulieu, J. Pouliot, J. Roy (Canada)
- Can we accrue to "difficult" trials in brachytherapy? 292
J. Crook, K. Wallace, N. Fleshner, M. Jewett (Canada)
- 1125 re-implantation in patients with poor initial dosimetry after prostate brachytherapy 293
M. Keyes, T. Pickles, A. Agranovich, W. Kwan, J. Morris (Canada)
- CT, MRI, and CT-MRI image fusion assessment for prostate I-125 post implant dosimetry 294
B. Al-Qaisieh, B. Carey, J. Evans, A. Flynn, D. Bottomley, D. Ash (United Kingdom)
- Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity following permanent interstitial brachytherapy 295
D. Reed, G. Merrick, A. Hinerman-Mulroy, W. Butler, K. Wallner, Z. Allen, E. Adamovich (U.S.A.)
- Permanent interstitial brachytherapy for younger patients with clinically organ-confined prostate cancer 296
D. Reed, G. Merrick, W. Butler, K. Wallner, R. Galbreath, E. Adamovich (U.S.A.)
- Dose escalation by HDR brachytherapy in intermediate or high risk localized prostate cancer: early toxicity and biochemical outcome of a pilot study 297
B. Guix, J.M. Bartrina, R. Serrate, J.I. Tello, I. Henríquez, J.R. Vendrell (Spain)



Posters



Abstract N°

Miscellaneous

- Multi phase radical treatment of anal cancer using concurrent chemo radiation and interstitial brachytherapy boost- Clatterbridge experience 298
A. Al-Hasso, A. Sun Myint, C.D. Lee, F. Jelley (United Kingdom)
- High dose rate brachytherapy (HDR) in endometrium carcinoma. Carlos Haya Hospital Experience in Malaga (Spain) 299
J.M. Azcoaga Blasco, I. Herruzo, I. Garcia, J. Macias, J. Contreras, I. Fortes, D. Rivas, A. Wals, R. Delgado, P. Galan (Spain)
- The intracoronary brachytherapy for in-stent restenosis: clinical and film dosimetric results 300
R. Baumann, A. Warszawski, H. Grundtke, B. Hornig, J.H. Karstens (Germany)
- Carcinoma of the oral tongue T1-T2 with positive margins. Postoperative brachytherapy 301
A.B. Bezares Alarcon, M. Martinez Carrillo, J. Martinez Galan, M. Zurita Herrera, E. Lopez Ramirez, V. Hernandez Garcia, A. Martinez Plaza, B. Garcia Medina (Spain)
- Interstitial HDR-brachytherapy in patients with oral cavity and oropharyngeal cancer treatment results and complications based upon material of Institute of Oncology in Gliwice 302
B. Bialas, W. Sasiadek, J. Bystrzycka, M. Fijałkowski, A. Wygoda, C. Szymczyk, A. Maciejewski, J. Wierzon, T. Rutkowski, K. Skladowski (Poland)

POSTERS

Posters



Abstract N°

- Three dimension conformal brachytherapy for medically inoperable endometrial carcinomas helps to define small bowell risk of toxicity 303
C. Brunaud, S. Hoffstetter, F. Ahmad, D. Peiffert, I. Buchheit, P. Aletti (France)
- Permanent prostate implants: information guide for patient and relatives 304
M. Chretien, J. Morrier, N. Varfalvy, L. Beaulieu (Canada)
- Early stage carcinomas of the mobile tongue: influence of modality treatment (curietherapy versus external irradiation combined with curietherapy) on local control and survival 305
S. Cordoba, J. Romero, A. de la Torre, F. Valcarcel, R. Magallon, C. Regueiro, M.I. Garcia Berrocal, I. Zapata (Spain)
- High dose rate (HDR) brachytherapy treatment for skin cancer 306
D.A. D'Souza, G.B. Rodrigues, O. Vujovic, M. Lock, A. Chan, F. Whiston, J. Taylor, J.A. Gilchrist (Canada)
- The role of high dose rate endobronchial brachytherapy in the palliation of patients with non-small cell lung cancer: a practice-guideline 307
C.B. Falkson, Y.C. Ung, E. Yu, J.A. Mackay, A. Haynes, W.K. Evans (Canada)
- Treatment of unresectable rectal cancers 308
J. Fontanesi, E. Janulionis, K.P. Valuckas, V. Atkocius, J. Kurtinaitis (U.S.A.)
- The role of external beam radiotherapy and brachytherapy in the treatment of bile duct and gall bladder tumors 309
C. Grehn, R. Krempien, F. Hensley, C. Berns, J. Debus, W. Harms (Germany)
- Effects of interstitial PDR and CLDR brachytherapy on cell cycle progression in a syngeneic rat prostate tumor model 310
W. Harms, P. Peschke, V. Ehemann, K. Weber, R. Krempien, C. Grehn, J. Debus (Germany)



Posters



Abstract N°

- Prostate specific antigen bounce after hormonal ablation, external beam radiation therapy and high dose rate brachytherapy in the treatment of prostate cancer 311
R. Ivker, B. Low, A. Helfman, S. Shoengold, A. Strumeyer, W. Chen, L. Bell (U.S.A.)
- High dose rate brachytherapy as conservative treatment for vulvar cancer 312
M. Jolicoeur, S. David, A. Devieux, T.V. Nguyen, P. Drouin, D. Provencher, P. Gauthier (Canada)
- Adjuvant High Dose Rate Brachytherapy alone or combined with external beam radiation in endometrial cancer 313
M. Jorge Lemos, M. Ortiz Monterrey, M.M. Sanchez Aragon, I. Monteiro Grillo (Portugal)
- Real-time intraoperative orientation for interstitial brachytherapy needle implantation using augmented reality 314
R. Krempien, H. Hoppe, S. Daeuber, C. Grehn, O. Schorr, J. Debus, W. Harms (Germany)
- Image fusion of CT and MRI data enables improved target volume definition in 3D-brachytherapy treatment planning 315
R. Krempien, S. Daeuber, F.W. Hensley, C. Grehn, H. Woern, J. Debus, W. Harms (Germany)
- CT images versus simulator images for dose planning of head & neck tumours 316
M. Lundell, J. Nilsson, S. Persson (Sweden)
- The role of high dose rate (HDR) brachytherapy in the management of soft tissue sarcomas 317
J. Maier, R. Patel, J. Fugazzi, D. Perry, M. Mott, E. Ben Josef, M. Yudelev, C. Zuniga, A. Frazier (U.S.A.)
- HDR and LDR brachytherapy in the treatment of paediatric tumours. A single institution experience on 21 patients 318
R. Mazzarotto, M.S. Buzzaccarini, G. Scarzello, A. Rigon, F. Vianello, G. Cecchetto, M. Carli, U. Cillo, G. Sotti (Italy)
- Pulsed dose-brachytherapy of oropharyngeal carcinomas 319
W. Melzner, M. Geiger, R. Sauer, V. Strnad (Germany)

POSTERS

Posters



Abstract N°

- A review of clinical application using Californium-252 320
J. Mignano, M. Rivard (U.S.A.)
- Adjuvant intravaginal high dose rate brachytherapy in 321
 endometrial adenocarcinoma
M. Ortiz Monterrey, M.M. Sanchez Aragon, M. Lemos, I. Monteiro Grillo (Portugal)
- Conservative treatment of intra-ocular melanoma with Iodine- 322
 125 brachytherapy
A.C. Pellizzon, R. Ferrigno, M. Maia, R. Fogaroli, J. Salvajoli, P. Novaes, M. Mottono, M. Chodjaniack (Brasil)
- A radiobiological model for the relative biological 323
 effectiveness of high dose rate Cf-252 brachytherapy
M. Rivard, H. Zinkin, L. Stapleford, K. Evans, J. Mignano, D. Wazer (U.S.A.)
- MEDARPA –Implantation of brachytherapy-catheters using 324
 augmented reality
S. Roddiger, D. Baltas, G. Sakas, M. Schnaider, S. Wesarg, P. Zogal, B. Schwald, H. Seibert, R. Kurek, N. Zamboglou (Germany)
- Neutron brachytherapy with Cf-252 low-dose-rate and concurrent 325
 chemotherapy in the treatment of primary cancer of the oral cavity
D. Semine, V. Medvedev, B. Vtyurin, Y. Mordynsky, V. Plichco, I. Gulidov, P. Isaev (Russian Federat)
- Effect and toxicity of palliative HDR and PDR brachytherapy in 326
 patients with recurrent head and neck cancer
J. Skowronek, M. Wierzbicka, M. Leszczynska, G. Zwierzchowski, W. Szyfter (Poland)
- High dose rate endobronchial brachytherapy in the management 327
 of advanced lung cancer - Comparison of different protocols
J. Skowronek, T. Piotrowski, W. Mlynarczyk, K. Adamska (Poland)



Posters



Abstract N°

- Intraluminal pulsed dose rate (PDR) brachytherapy for locally advanced bile ducts cancer: a case report 328
J. Skowronek, A. Sowier, P. Skrzywanek, G. Zwierzchowski (Poland)
- Brachynet - A brachytherapy database and information management system 329
R. Smith, J. Millar, M. Millar (Australia)
- Esophageal fistula formation following esophageal wall resection and permanent radioactive seed implantation for mediastinal carcinoid tumors 330
A. Stewart, D.A. O'Farrell, J. Kazakin, R. Bueno, D.J. Sugarbaker, R.A. Cormack, P.M. Devlin (U.S.A.)
- Comparison of results with external beam irradiation (EBI) or EBI + interstitial high dose rate (HDR) brachytherapy (BT) in the treatment of base of tongue tumors 331
Z. Takacsi-Nagy, F. Oberna, C. Polgar, A. Somogyi, T. Major, J. Fodor, G. Nemeth (Hungary)
- Update of HDR-brachytherapy for non-malignant obstruction in lung transplant bronchi: two years experiences 332
A. Warszawski, R. Baumann, T. Möller, J. Niedermeyer, J.H. Karstens (Germany)

POSTERS

Author index

Abdessaied, S.	187	Ash, D.	34, 41, 68, 103, 193, 294
Abner, A.	220	Aslay, I.	163, 207
Abonante, S.	141	Astrom, L.	196
Adamovich, E.	38, 40, 194, 257 270, 281, 295, 296	Atahan, I.L.	115, 147
Adamska, K.	327	Atkocius, V.	308
Adli, M.	53	Axelrod, S.	183
Agranovich, A.	293	Azario, L.	190
Aguayo, M.	46, 137	Azcoaga, J.M.	154, 198, 299
Aguilo, F.	35	Aziza, R.	251
Ahmad, F.	165, 192, 303	Bachaud, J.M.	251
Akinci, M.	207	Bagiella, E.	227, 260
Akyol, F.	115	Bakhshinyan, E.	148
Al-Hasso, A.	298	Ballardini, B.	142
Al-Qaisieh, B.	34, 41, 68 103, 193, 294	Ballester, F.	81, 173, 182
Alas, R.	163	Baltas, D.	29, 91, 210, 324
Albano, M.	14	Baños, M.C.	191
Albuquerque, K.	127	Bar-Deroma, R.	146
Alcalde, J.	122	Barakat, R.	50, 51
Alektiar, K.	50, 51, 56	Baranzelli, M.	143
Aletti, P.	165, 192, 303	Barbieri, J.	259
Alezra, D.	153	Bartlova, R.	138
Alfia, H.	228	Bartrina, J.M.	234, 249, 279, 297
Allbright, R.	116	Battermann, J.	44, 59, 152 208, 253, 265
Allen, Z.	40, 194, 195, 281, 295	Bauer, N.	23, 151
Altieri, G.	57	Baumann, R.	300, 332
Alves, M.J.	159	Bea, J.	191
Amendola, B.	135	Beard, C.	87
Amendola, M.	135	Beato, I.	46
Amillo, S.	122	Beaulieu, L.	10, 13, 70, 179 235, 267, 291, 304
Amirabadi, A.	66	Beckmann, M.W.	76
Amit, A.	146	Béjar, A.	170, 171
Ammor, A.	258	Bejarano, M.	242
Anagnostopoulos, G.	29	Belkacemi, Y.	65, 143, 167
Andrews, J.	252	Bell, L.	311
Angermeier, K.	39, 43, 88 108, 277	Bellon, J.R.	144
Angyalfi, S.	211	Ben Ayed, F.	161
Ansbacher, W.	78, 175	Ben Josef, E.	317
Antal, G.	156	Ben Romdhane, K.	161
Antonelli, C.	117	Ben-Porat, L.	269
Arcusa, A.	155	Ben-Shachar, I.	19
Armour, E.	57	Benko, A.	156
Aronowitz, J.	245	Benna, F.	161, 187
Arribas, L.	46, 137	Beny, A.	146
Arterbery, E.	250	Berle, L.	74
Arthur, D.	77, 133	Berniger, A.	146
Asadpour, B.	282	Berns, C.	130, 309
		Bernstein, Z.	146

Author index

Bertelsman, C.	268, 280	Buhleier, T.	91
Besbes, M.	161, 187	Bui, B.N.	123
Beyer, D.	60, 197	Bulgheroni, A.	97
Bezares Alarcon, A.B.	84, 301	Bulski, W.	2
Bhatia, S.K.	272	Burdette, E.	266
Bialas, B.	224, 302	Burdette, E.C.	233
Bialas, F.	212	Burette, R.	214
Bianchi, C.	97, 180	Buron, C.	72
Biete, A.	155	Butler, W.	38, 40, 194, 195, 257, 270, 281 295, 296
Bilbao, P.	49, 131	Buzzaccarini, M.S.	318
Bladou, F.	35, 200	Bystrzycka, J.	224, 302
Blank, L.	172, 274	Caccia, M.	97, 180
Blasko, J.C.	33	Cacicedo, J.	73
Bloch, N.B.	11	Cady, B.	74
Block, T.	231, 238	Cambeiro, M.	122
Blumstein, N.M.	228, 247	Cambria, R.	178
Bodineau, C.	154, 198	Camphausen, K.	219
Bogner, P.	156	Camps, J.	188
Bohlin, G.	217	Canino, P.	142
Boladeras, A.	73	Capote, R.	190
Bonaventura, M.	129	Cappellini, C.	97, 180
Bonet, M.	218	Capuz, A.	242
Bonnet, J.	83, 251	Carballo, N.	150
Bonneviale, P.	123	Cardarelli, G.	77
Bonodeau, F.	143	Carey, B.	34, 41, 68 103, 193, 294
Borchers, H.	254, 282, 283	Carli, M.	318
Bornstein, B.	77	Carlson, T.	108, 277
Böswarth, J.	23	Carrasco, P.	93, 218
Bottomley, D.	34, 41, 68, 103 193, 294	Carrascosa, M.	46, 137
Bourgier, C.	118	Carroll, P.	197
Bouwman, R.	9	Casal, E.	81, 173, 182
Bouzy, J.	14, 45	Casana, M.	46
Boveda, E.	49, 131	Casas, F.	155
Bownes, P.	241	Cases, R.	81, 173, 182
Brabbins, D.	104, 112	Casquero, F.	49, 131
Brearley, E.	68	Castaigne, D.	45
Breitman, K.	211	Castelain, B.	118, 167
Breuille-Fouché, M.	54	Castellanos, M.	118, 143
Briot, E.	25, 45, 149	Castillo-Lopez, B.	199
Brookover, W.	36, 244	Catane, R.	153
Brown, M.	206	Cattani, F.	142, 178
Brunaud, C.	165, 192, 303	Cavanagh, W.	248, 268, 280
Bruzzone, M.	166	Cecchetto, G.	318
Bryant, L.	241	Celeiro, J.	131
Bucci, J.	111	Cengiz, M.	115, 147
Buchheit, I.	303	Cesaretti, J.	290
Buchholz, T.	64	Ceylan, C.	152
Budinsky, A.	126		
Bueno, R.	330		

Author index

Chan, A.	306	Crelgo, D.	230
Chan, H.	37, 67	Crispens, M.	17
Charra-Brunaud, C.	271	Crook, J.	66, 124, 205, 292
Chauveinc, L.	72, 109, 114	Cselik, Z.	156
Chauvet, M.	143	Cuttino, L.W.	133
Chemin, A.	83	Cygler, J.	55, 206, 209
Chen, H.	107	Czembirek, C.	145
Chen, L.	24	Czempiel, H.	231, 238
Chen, M.	48	Czerminka, M.A.	144
Chen, P.	104, 112	D'Amico, A.	87
Chen, W.	311	D'Olieslager, G.	172, 274
Cher, M.	261	D'Souza, D.A.	306
Cher, M.L.	250	Daeuber, S.	314, 315
Chevallier, A.	167	Dal Pozzo, C.	226
Chevreau, C.	123	Dale, R.	101
Chi, D.	50, 51	Daly-Schweitzer, N.	83, 123
Chirat, E.	258	Damyanovich, A.	66
Chiu-Tsao, S.	183	Dannenber, T.	210
Chiva, L.	150	David, S.	52, 312
Cho, P.	287	Davis, B.	221
Chodjaniack, M.	322	Ddumas, I.	149
Choo, R.	86	De Brabandere, M.	8, 25
Chrenko, V.	138	De Camargo, B.	117
Chretien, M.	304	De Crevoisier, R.	54, 258
Chung, M.	74	de Kruijff, W.J.M.	95
Chust, M.L.	137	de la Torre, A.	305
Ciezki, J.	39, 43, 88, 108, 277	de la Torre M.	6
Cillo, U.	318	de Reijke, T.	274
Ciocca, M.	142	Debré, B.	109, 114
Citrin, D.	219	Debus, J.	130, 309, 310, 314, 315
Clouser, E.	96	DeFilippo, J.	194
Coche-Dequeant, B.	118	Del Duca, D.	286
Cohen, G.	37, 56, 67, 222, 269, 272	Del Duca, M.	226
Colella, J.	227, 260	Del Hoyo, O.	49, 131
Coleman, C.	219	Del Moral-Ávila, R.	84
Concejo, C.	122	Delannes, M.	72, 83, 123, 251
Condon, O.	160	Delclos, L.	32
Conte, L.	97, 180	Delgado, J.	242
Contreras, J.	154, 198, 299	Delgado, R.	154, 299
Corbusier, A.	214	Demanes, J.	57
Cordoba, S.	305	Demirel, G.	283
Cormack, R.	11, 87, 144, 330	Deneufbourg, J.M.	289
Cosset, J.	72, 109, 114	DeOreo, G.	39
Costa, A.	142	Derakhshani, P.	89, 110, 232, 262, 263
Court, B.	258	Desgrandchamps, F.	276
Coza, O.F.	157, 158	Devieux, A.	52, 312
Craven-Bartle, J.	155, 218	Devlesaver, P.	214
Crawford, D.	105	Devlin, P.M.	144, 330

Author index

DeWerd, L.	30	Falk, J.	129
Di Muzio, N.	35, 286	Falkson, C.B.	307
Di Stefano, C.	226	Farrús, B.	155
Diaz, F.	198	Feijóo, M.	213
Dicker, A.	71	Fellin, G.	286
Dietrich, J.	128	Fernandez, J.	223, 230
Dimopoulos, J.	20, 22, 23, 25	Ferrarini, M.	166
	151	Ferré, F.	54
DiPetrillo, T.	74, 77, 139	Ferrigno, R.	16, 48, 117, 275
Djemil, T.	88		322
Doggett, S.	266	Fidanzio, A.	190
Drapeau, M.	116	Fijalkowski, M.	224, 302
Drouin, P.	52, 312	Finestres, F.	234
Drumea, K.	146	Firat, S.	21
Dubuc, J.	52	Firmin, F.	109, 114
Dumane, V.A.	222	Fischedick, K.	282, 283
Dumas, I.	25	Fizaki, K.	258
Dunscombe, P.	211	Flam, T.	72, 109, 114
Dunst, J.	15, 162	Fleckenstein, J.	215
Duvillard, P.	54	Fleming, P.	96
Eastham, J.	107	Fleshner, N.	292
Eble, M.J.	254, 282, 283	Flynn, A.	68, 294
Edgren, M.	217	Flynn, J.	36, 244
Edmundson, G.	57, 104, 112	Fodor, J.	79, 331
Egberts, J.	255	Fogaroli, R.	16, 48, 117, 275,
Ehemann, V.	310		322
Eifel, P.	98	Follette, J.	245
Ekstrand, K.E.	204	Fontanesi, J.	308
El Boussairi, H.	14, 45	Foppiano, F.	166
Elders, L.	9, 174	Ford, E.	287
Elliott, E.	17	Forestier, S.	192
Ellison, T.	3, 5	Forman, J.D.	250
Elshaikh, M.	108, 277	Fortes, I.	154, 299
Emiliani, E.	226	Fournier, C.	118
Erickson, B.	21	Fowler, J.	19
Esche, B.	124	Franzone, P.	166
Escobar, J.	288	Frazier, A.	47, 250, 261, 317
Escolar, P.	46, 137	Friedlich, M.	55
Espinosa, J.M.	49	Friedrich, C.	17
Espinosa, M.	170, 171	Frikha, H.	161, 187
Eudaldo, T.	93, 218	Fugazzi, J.	47, 317
Evans, D.	201, 211	Fuks, Z.	37
Evans, J.	294	Gaballa, H.	185
Evans, K.	323	Gabayan, A.	125
Evans, V.	42	Gadient, T.	202
Evans, W.K.	307	Gagel, B.	254
Fagundes, H.	268, 280	Galalae, R.	255
Fagundes, L.	248	Galan, P.	198, 299
Fagundes, M.	248	Galbreath, R.	38, 40, 195,
Fait, V.	138		257, 270, 281, 296

Author index

Garcia Berrocal, M.I.	305	Grills, I.S.	57
Garcia Medina, B.	301	Grimaldi, L.	190
Garcia Rios, I.	154, 198, 299	Grimard, L.	55, 124
Garcia, J.M.	49	Grimm, P.D.	7, 33
García, M.A.	191	Grossheim, L.	21
Garcia, S.	170, 171	Grundtke, H.	300
Gargourdi, W.	187	Guedea, F.	1, 3, 4, 5, 35, 73
Gargouri, W.	161	Guerif, S.	72
Garibaldi, C.	178	Guillem, J.	56
Garrán, C.	122	Guinot, J.	46, 137
Garza, R.	127	Guix, B.	75, 234, 249, 279, 297
Gauthier, P.	52, 312	Gulidov, I.	325
Gavris, S.	157, 158	Gurdalli, S.	115, 147
Geiger, M.	319	Gustafson, G.	104, 112, 219
Gejerman, G.	12, 227, 259, 260	Gustafson, G.S.	57
Geltzeiler, J.	105	Gutiérrez, C.	73
Geltzeiler, M.	105	Guzman-Ruiz, L.	199
Gennari, R.	142	Gysbrechts, S.	188
Georg, D.	8, 22, 151, 273, 285	Hadjiev, J.	156
George, R.	133	Haensgen, G.	15, 162
Germeau, F.	214	Haggman, M.	217
Gerszten, K.	129	Haider, M.	205
Gez, E.	146	Haie-Meder, C.	14, 25, 45, 54, 149, 258
Ghilezan, M.	57, 104, 112	Hallil, A.	206
Giannelli, F.	166	Hammer, J.	76
Giannini, M.	226	Han, I.	47
Giard, S.	143	Hanley, J.	12, 259
Gic, I.	155	Hansen, J.	144
Gilchrist, J.A.	306	Hansen, S.	140
Gilson, P.	202	Harel, F.	70
Gnani, G.	226	Harms, W.	130, 309, 310, 314, 315
Goffin, F.	52	Harrison, L.	183
Goicoechea, M.	49, 131	Hautmann, R.E.	228
Goldner, G.	20	Hawliczek, R.	11
Gómez de Segura, G.	218	Haynes, A.	307
Gonzalez, J.	223	Hechtman, C.	177
Gonzalez, J.M.	230	Heide van der, U.A.	152
Gottfried, H.-W.	228/, 247	Helbich, T.	20
Gould, K.	34	Helbich, T.H.	11
Graham, R.	74	Helfman, A.	311
Granero, D.	81, 173, 182	Henderson, A.	85, 113
Graves, T.	74	Henkel, T.O.	69
Gravis, G.	200	Hennequin, C.	276
Gray, Y.	86	Henriquez, I.	75, 234, 249, 279, 297
Grebler 2, A.	105	Hensley, F.	130, 309, 315
Grehn, C.	130, 309, 310, 314, 315	Hensley, F.W.	315
Grigoriev, E.	97, 180		
Grigsby, P.	53, 177		

Author index

Hepel, J.	121	Jurgenliemk-Schulz, I.	265
Herk van, M.	236	Jürgenliemk-Schulz, I.M.	152
Herman, M.	221	Kader, H.A.	78, 175
Hernandez Garcia, V.	301	Kahmann, F.	69
Hernández, V.	84	Kalkner, K.M.	217
Hernández-Lizoain, J.	122	Kantor, G.	893
Heron, D.E.	129	Kaplan, I.D.	11
Herruzo Cabrera, I.	154, 198, 299	Kaplan, Y.	282
Hervás, A.	242	Kapulsky, A.	12, 259, 260
Hevezi, J.	860	Karlsson, L.	119
Hildebrandt, G.	76	Karstens, J.H.	300, 332
Hinerman-Mulroy, A.	195, 295	Kataja, V.	35
Hoekstra, C.	9, 174	Kattan, M.	107
Hoffstetter, S.	192, 303	Katz, S.	246
Holupka, E.	11, 220, 233	Kaufman, S.	77
Holy, R.	254, 282	Kawczynska, M.	2
Hoppe, H.	314	Kay, I.	201, 211
Hornig, B.	300	Kazakin, J.	144, 330
Hoskin, P.J.	241	Keenan, D.	129
Hsiang, J.	116	Keisch, M.	62
Hsu, I.	24, 240, 243, 267 271, 278	Kelley, J.	129
Huang, D.	290	Kelly, C.	92, 184
Huang, K.	24	Kelly, D.	36, 225, 229, 237, 244
Hurwitz, M.	87	Kemikler, G.	163, 207
Husain, S.	211	Keole, S.	47
Huyghe, E.	251	Keselman, I.	105
Huyskens, D.	8	Kestin, L.	104, 112
Immerzeel, J.	9, 174	Ketelaars, M.	152
Ingram, G.	237, 244	Keyes, M.	111, 293
Isaev, P.	325	Keys, R.	268, 280
Ivker, R.	311	Khangel'dyan, A.	148
Jakse, G.	254, 282, 283	Khuntia, D.	277
Jansen, N.	289	Kim, H.	71
Janulionis, E.	308	Kim, Y.	278
Jaskiewicz, J.	136	Kimmig, B.	128, 255
Jassem, J.	136, 189	Kirilova, A.	66
Jelley, F.	298	Kirisits, C.	8, 20, 22, 23, 25 126, 151, 273, 285
Jerez, I.	154, 198	Kiseleva, M.	169
Jewett, M.	292	Klein, E.	39, 43, 88, 108, 277
Jeziorski, J.	124	Knocke, T.	23, 145
Johansson, B.	119	Kochbati, L.	161, 187
Johnson, R.	129	Koedooder, C.	274
Jolicoeur, M.	52, 312	Koedooder, K.	172
Jonca, F.	251	Kohr, P.	128
Jorge Lemos, M.	160, 313	Kolarik, V.	164
Jornet, N.	93, 218	Kolkman-Deurloo, I.K.K.	95
Joseph, J.	34, 41, 103, 193	Kollmeier, M.	290
Juan, G.	223		
Jurado, M.	122		

Author index

Korb, L.	203	Lemos, M.	321
Korba, A.	202	Lennernas, B.	217
Kort de, G.A.P.	152	Leon, C.	155
Koutrouvelis, P.G.	246	Lessard, E.	24, 179, 219, 235 240, 267, 271, 278
Kovacs, G.	58, 63, 128, 255	Leszczynska, M.	326
Kramar, A.	14, 45	Létourneau, A.	235
Kramer, B.	244	Levendag, P.C.	95, 120
Krempien, R.	130, 309, 310, 314 315	Levey, S.	227
Krenkel, B.	282	Levin, D.	153
Krikunova, L.	168, 169	Li, Z.	177
Kucewicz, W.	97	Licht, N.	215
Kucucuk, S.	163	Lief, J.	38, 40, 195, 257
Kuhnt, T.	162	Linehan, R.	107
Kurek, R.	91, 210, 324	Lippert, M.	264
Kurhanewicz, J.	90, 278	Lis, M.	81
Kurtinaitis, J.	308	Litvin, S.	105
Kuske, R.	61	Liu, H.	186
Kuten, A.	146	Liwartovski, A.	72
Kwan, W.	293	Llácer, C.	83, 123
Lachaine, M.	125	Llorente Manso, M.	150
Lachance, B.	179, 235, 267	Lo, S.	47
Lacornerie, T.	118, 143	Lo, T.	106
Lacorte, T.M.	279	Loayza, A.	49
Lailas, N.	246	Loblaw, D.	86
Laing, R.	35	Loch, T.	215, 255
Laing, R.W.	85, 113	Lock, M.	306
Lamoreaux, W.	53	Lockett, M.	288
Landis, D.	87	Lockwood, G.	205
Lang, K.	212	Longobardi, B.	286
Lang, S.	8, 20, 22, 23, 25 151, 273, 285	Lopez Penalver, C.	135
Langley, S.	35, 85, 113	López Torrecilla, J.	3
Lanteri, V.	227	López, E.	191
Lapeyre, M.	192	López, M.	171
Larrea, L.	191	Lopez, M.D.	170
Lartigau, E.	118, 143, 167	López-Ramírez, E.	84, 301
Lavagnini, P.	286	Lorusso, R.	180
Lavallé, M.-C.	10	Lotter, M.	76
Lavallée, M.-C.	13	Lou, C.	135
Lazzari, R.	142	Low, B.	311
Leblanc, E.	167	Lowe, G.J.	241
Lebrun, B.	70	Luna, V.	230
Leclerc, G.	10	Lundell, M.	316
Lee, C.D.	132, 298	Lyczek, J.	2
Lee, J.	80	Maalej, M.	161, 187
Lee, W.R.	204	Maathiwitz, G.	220
Lei, F.	186	Macias, J.	154, 198, 299
Leibel, S.	37, 107	Maciejewski, A.	302
Lejarcegui, J.A.	75	Mackay, J.A.	307
		Magallon, R.	305

Author index

Magela, G.	213	Mengual, J.	46
Mager, R.	283	Mengual, J.L.	137
Mahadevan, A.	11, 39, 43, 88, 277	Menhel, J.	153
Mai, J.	21	Merrick, G.	38, 40, 194, 195, 257, 270, 281, 287, 295, 296
Maia, M.	16, 48, 117, 275, 322	Meskill, P.	11, 220, 233
Maier, J.	261, 317	Messer, P.M.	228, 247
Maitland, C.	261	Metayer, Y.	165
Major, T.	63, 79, 331	Metz, J.	89, 110, 232, 262, 263
Malik, Z.	132	Meyskens, J.	188
Malmgren, J.A.	33	Michalski, J.	288
Mamouhdieh, A.	235	Michaud, S.	276
Mangili, P.	286	Miglietta, L.	166
Mansur, D.	177, 288	Mignano, J.	320, 323
Marafioti, L.	141	Mignot, T.M.	54
Marchesi, V.	192	Milickovic, N.	29
Marcos, F.	49, 131	Millar, J.	329
Maroun, J.	55	Millar, M.	329
Martel, P.	83, 123	Miller, R.	219
Martens, M.J.	188	Minar, E.	126
Martin, A.-G.	10, 70, 291	Minsat, M.	83, 123
Martin, T.	91, 210	Minsky, B.D.	56
Martinez Carrillo, M.	301	Mirzaei, M.	204
Martinez Galan, J.	84, 301	Mkrtchyan, L.	168
Martinez Plaza, A.	301	Mlynarczyk, W.	327
Martinez, A.	57, 104, 112	Moerland, M.	265
Martinez, J.	150	Moerland, M.A.	208, 253
Martinez-Carrillo, M.	84	Mogus, R.	129
Martinez-Monge, R.	122	Möller, T.	332
Master, V.	197	Monteiro Grillo, I.	160, 313, 321
Mathiowitz, G.	11	Montero, A.	242
Mathur, N.	67	Moonen, L.M.F.	236
Maurer, G.	212	Moorthy, C.R.	176
Maurer, U.	35, 212	Morash, C.	209
Maxey, R.	17	Moravan, V.	111
Maylin, C.	276	Mordynsky, Y.	325
Mazeron, J.J.	4, 99	Morelli, M.	226
Mazzarotto, R.	318	Moreno, F.	73
Mazzotti, G.	226	Morera, R.	242
McElveen, T.	71	Morice, P.	14, 54
McLaughlin, P.	42	Moris, R.	242
McLean, M.	205	Morrier, J.	13, 304
McLeod, D.	197	Morris, J.	293
Medvedev, V.	325	Morris, W.J.	111
Meier, R.	33	Morton, G.	86
Meigooni, A.S.	27	Motono, M.	322
Melzner, W.	319	Mott, M.	317
Membrive, I.	218	Moyana, T.	55
Menard, C.	219, 267		
Menegussi, G.	159		

Author index

Mozzanica, A.	97	O'Farrell, D.A.	144, 330
Múglia, R.	213	O'Reilly, P.	92
Mullokanov, E.	260	Obedian, E.	185
Munoz, E.	170, 171	Oberna, F.	331
Murray, K.	21	Ocampo, P.	92, 184
Muskalla, K.	89, 110	Oismueller, R.	11
	232, 262, 263	Okutan, M.	163
Nag, S.	19	Olivotto, I.A.	78
Nakamura, R.	117	Olszyk, O.	167
Nanavati, P.	17	Ordeanu, C.	157, 158
Napoli, J.	12, 259, 260	Orecchia, O.	178
Narayana, V.	42	Orecchia, R.	142
Narducci, F.	167	Oriolo, V.	141
Nasr Ben Ammar, C.	161, 187	Ortiz de Zarate, R.	131
National Cancer Analysis Team	4	Ortiz Monterrey, M.	160, 313, 321
Nava, L.	35	Ostertag, H.	128
Navarro, M.	84	Ostler, P.J.	241
Navarro, V.	73	Ott, O.J.	76
Nayak, R.	107	Ozby, I.	207
Ndlovu, A.M.	12	Ozyar, E.	115, 147
Ndlovu, A.	259, 260	Pacyna, L.	133
Nebout, N.	114	Pai, R.	78
Nemeth, G.	331	Palacios, A.	170, 171
Neubauer, S.	89, 110	Palazzi, S.	226
	232, 262, 263	Palombo, H.	75
Nevelsky, A.	146	Pamanes-Ochoa, A.	199
Ng, W.S.	186	Panades, M.	78, 175
Nguyen, N.	116	Papirek, T.	164
Nguyen, T.V.	52, 149, 312	Pardo, F.	122
Nickers, P.	289	Paris, B.	54
Nied, L.	248	Patel, R.	47, 261, 317
Niedermeyer, J.	332	Paty, P.B.	56
Niehoff, P.	63, 128, 255	Pearson, S.	205
Niewald, M.	215	Peiffert, D.	4, 72, 165, 192, 303
Nijdam, W.	120	Pellizzon, A.	48, 117, 275, 322
Nilsson, J.	316	Pellizzon, A.C.A.	16
Nilsson, S.	217	Pellizzon, A.C.P.	159
Ning, H.	219, 267	Pellizzon, R.	275
Nishimoto, I.	48	Perez, C.	288
Nisin, R.	3, 4, 5	Pérez-Calatayud, J.	81, 173, 182
Noé, L.	188	Perkova, H.	138
Noél, A.	192	Perrone, F.	190
Noever, I.	120	Perry, D.	250, 261, 317
Nori, D.	116	Perry, G.	206, 209
Novaes, P.	16, 48, 117, 159, 275, 322	Persson, S.	316
Novario, R.	180	Peschke, P.	310
Nulens, A.	25	Pessoa, E.L.	159
Nürnberg, N.	255	Pesudo, C.	46
O'Dell, W.	186	Petit, C.	149

Author index

Petrow, P.	25, 149	Reed, D.	38, 40, 194, 195 257, 270, 281, 287 295, 296
Pfeffer, R.	153	Regueiro, C.	305
Phillips, M.	203	Reizenstein, J.	119
Phlips, P.	109	Repa, I.	156
Piazzzi, V.	142	Resch, A.	76
Pickett, B.	90, 252	Ribas, M.	93, 218
Pickles, T.	293	Rieke, J.	140
Piermattei, A.	190	Rigon, A.	318
Pieters, B.	172, 274	Rivard, M.	26, 77, 139, 181 201, 320, 323
Pinkawa, M.	254, 282, 283	Rivas, D.	154, 299
Pinto, L.	213	Roach, M.	90, 252
Piotrowski, T.	327	Robb, R.	221
Pipman, Y.	185	Roberson, P.	42
Piro, F.	141	Roddiger, S.	91, 210, 324
Pla, C.	191	Rodero, P.	198
Plante, P.	251	Rodrigues, G.B.	306
Plichco, V.	325	Rodriguez Villalba, S.	150
Poetter, R.	126	Rodriguez, A.	230
Pokrajac, B.	126	Rodriguez, I.	242
Polgar, C.	63, 79, 331	Rodriguez, M.	170, 171
Polo, A.	178	Rodriguez, R.	57
Pommier, P.	72	Rogge, B.	210
Pond, G.	124	Romeo, J.	171
Popescu, C.C.	175	Romeo, J.L.	170
Pötter, R.	20, 22, 23, 25, 76 102, 145, 151, 273	Romero, J.	305
Pouliot, J.	24, 179, 219, 235 240, 267, 271, 278, 291	Romick, B.	202
Poupon, L.	167	Rondi, E.	178
Prada, P.	223	Rosemberg, S.	261
Prasad, D.	264	Rosenblatt, E.	146
Prestidge, B.	80	Rosenthal, A.	80
Prevost, B.	118	Rosenwald, J.	109, 114
Provencher, D.	52, 312	Roth, R.	106
Ptackova, B.	18	Rothschild, J.	74
Puchades, V.	173, 182	Röttinger, E.M.	228, 247
Puthawala, A.	121, 134	Rovirosa, A.	82, 155
Quan, A.	39	Rownd, J.	21
Raben T, A.	105	Roy, J.	70, 291
Raben, D.	105	Rübe, C.	215
Radden, M.	268, 280	Rubens, D.	186
Rahal, K.	161	Ruiz Lopez, A.	150
Ramos, A.	242	Ruiz, B.	49, 131
Rawlins, C.L.	129	Rusch, T.	140, 181, 183
Razek, A.	202	Rutkowski, T.	302
Razzaq, M.	233	Rutten, J.A.	188
Rebo, I.	12, 259, 260	Ruzickova, J.	138
Reddy, C.	39, 43, 88, 108, 277	Sa Brito, C.	248
		Sadeghi, A.	80

Author index

Sahlen, G.	217	Shaffer, J.	17
Sakas, G.	324	Shah, N.	77
Salem, N.	35, 72, 200	Shah, S.	202
Salinas, L.	80	Sharma, A.	121, 134
Salmanova, K.	168	Shentereva, N.	168
Salvajoli, J.	16, 48, 117 159, 275, 322	Shinohara, K.	197
Samm, W.	202	Shoengold, S.	311
Sampietro, C.	97, 180	Siarni, P.	202
San Julián, M.	122	Siegel, A.	227
Sanan, A.	125	Sierra, J.	155
Sanchez Aragon, M.M.	313, 321	Silvern, D.A.	176
Sanchez, P.	230	Sim 2, S.	105
Sancho, G.	218	Simonian, M.	200
Sancho, S.	242	Sitathanee, C.	19
Santos Ortega, M.	150	Sjoden, P.-O.	217
Saoudi, A.	206, 209	Skladowski, K.	302
Sasiadek, W.	302	Skowronek, J.	94, 326, 327, 328
Sauer, R.	76, 319	Skrzywaneck, P.	328
Sawczuk, I.	227, 259, 260	Slampa, P.	138
Scardino, P.	107	Slosarek, K.	224
Scarzello, G.	318	Slotman, B.J.	5
Schard, G.	20	Smith, B.	202
Schellenberg, D.	111	Smith, R.	329
Scheuch, J.	227	Snee, A.	132
Schmid, R.	126	Solignac, S.	109, 114
Schnaider, M.	324	Somogyi, A.	331
Schneider, B.	264	Sooriakumaran, P.	91, 113
Schneider, C.J.	236	Sorensen, A.	202
Schneider, E.	228, 247	Sotti, G.	318
Schokker, R.I.	208	Soulié, M.	251
Schorr, O.	314	Soumarova, R.	138
Schour, L.	57	Sowier, A.	328
Schultz, D.	87	Speight, J.	24, 240, 267
Schulz, I.	253	Spira, G.	89, 110, 232, 262, 263
Schwald, B.	324	St Clair, S.	103
Scolaro, T.	166	Stapleford, L.	323
Scrofino, S.	227, 260	Stea, B.	125
Sebastian, E.	104, 112	Steggerda, M.J.	236
Seguin, P.	251	Stern, H.	55
Seibert, H.	324	Stewart, A.J.	144, 330
Selek, U.	147	Stickney, E.	271
Semine, D.	325	Stock, R.	290
Seo, H.	107	Stoeckle, E.	83, 123
Serkies, K.	136, 189	Stone, N.	290
Serment, G.	200	Strang, P.	217
Serrate, R.	234, 249, 279, 297	Strauss, H.	15, 162
Sethi, A.	127	Strnad, V.	18, 76, 319
Severgnini, M.	178	Strumeyer, A.	311
Severini, G.	226	Su, Y.	221

Author index

Suarez-Campos, J.	199	Troyer, S.	42
Suciu, D.	157, 158	Truong, P.T.	78, 175
Sugarbaker, D.J.	330	Tsao, H.	183
Sulkhanyan, R.	148	Tsvang, L.	153
Sun Myint, A.	298	Tudela, L.	170, 171
SunMyint, A.	132	Tunn, U.W.	91, 210
Susil, R.	219	Ulchaker, J.	39, 43, 88, 108 277
Syed, A.	121	Ung, Y.C.	307
Syed, N.	134	Usategui, B.	131
Sylvester, J.E.	33	Utzig, D.	15
Symon, Z.	153	Uyl-de Groot, C.	120
Szyfter, W.	326	Vacher-Lavenue, M.C.	54
Szymczyk, C.	302	Valcarcel, F.	305
Tacchini, L.	166	Valentine, K.	87
Tacev, T.	18, 164	Valuckas, K.P.	308
Taieb, S.	167	van 't Riet, A.	9, 174
Takacsi-Nagy, Z.	331	van Agthoven, M.	120
Tanzi, F.	180	van de Bunt, L.	152
Tarnawska, Z.	136, 189	van der Grient, H.	274
Taussky, D.	66, 205	van der Grient, J.	172
Taylor, J.	306	Van der Laarse, R.	28
Teillac, P.	276	van der Poel, H.G.	236
Tekyi-Mensah, S.	47	Van Deursen, M.J.H.	208
Tello, J.I.	75, 234, 249, 279, 297	van Dijk, E.	31
Tempany, C.	87	Van Gellekom, M.P.R.	253, 265
Tenekeci, N.	207	Van Limbergen, E.	25, 102
Tenenholz, T.	77	van Wieringen, N.	172
Tereffe, W.	56	Vanderick, J.	214
Theodore, C.	258	VanderMeersch, S.	17
Theodorescu, D.	246, 264	Varfalvy, N.	13, 304
Thiounn, N.	109, 114	Vargas, C.	57, 104, 112
Thirion, P.	92	Vavassori, A.	142, 178, 286
Thissen, B.	289	Vaz, F.	213
Thomadsen, B.	30	Veltri, M.	141
Thomas, L.	883, 123	Vendrell, J.R.	234, 249, 279, 297
Thomson, I.	206	Venkatraman, E.	50
Thoulouzan, M.	251	Venselaar, J.	5, 8, 81
Thuret, R.	276	Vianello, F.	318
Ticha, H.	138	Vicini, F.	104
Tidwell, T.J.	216	Vicni, F.	112
Tiggelaar, R.	172	Vigneault, E.	10, 70, 179, 235 267, 291
Timbert, M.	109, 114	Vigneron, D.B.	278
Todor, D.A.	133	Villanueva, A.	198
Töre, G.	163	Vitale, V.	166
Tortajada, M.	46, 137	Vivanco, J.	230
Tosi, G.	178	Vtyurin, B.	325
Tremblay, C.	179, 235	Vujovic, O.	306
Treusacher, H.	283	Wachter, S.	20, 151, 273, 285

Author index

Wachter-Gerstner, N.	20, 22, 23, 25, 151	Wong, W.D.	56
Walczak, A.	2	Woolfenden, J.	125
Wallace, K.	292	Worman, M.F.	222
Wallner, K.	38, 40, 194, 195, 257, 270, 281, 287, 295, 296	Wust, P.	69
Wals, A.	154, 299	Wygoda, A.	302
Wambersie, A.	102	Wynstra, J.	17
Warnier, P.	214	Yajnik, S.	239
Warszawski, A.	300, 332	Yamada, J.	37, 272
Waterman, F.	71	Yamada, Y.	67, 107, 239
Watson, R.	227	Yan, D.	57
Wazer, D.	74, 77, 139, 323	Yang, J.	105
Weber, K.	310	Yazici, G.	115
Weidhaas, J.	51	Yeung, I.	205
Weinberg, V.	24, 271	Yildiz, F.	115, 147
Weiser, M.R.	56	Ypma, F.	9, 174
Weitmann, H.D.	145	Yu, E.	307
Wesarg, S.	324	Yu, Y.	186
Westendorp, R.	9, 174	Yudelev, M.	250, 261, 317
Whiston, F.	306	Zaider, M.	37, 56, 67, 100 222, 269, 272
White, J.	140	Zakian, K.	67
Wibault, P.	258	Zaloudik, J.	138
Wierzbicka, M.	326	Zamboglou, N.	91, 210, 324
Wierzgon, J.	302	Zanon, G.	75
Wijrdeman, H.	265	Zapata, I.	305
Wijrdeman, H.K.	253	Zelesky, M.	37, 51, 56, 67, 107 239, 269, 272
Wilkins, D.	209	Zheng, Z.	77, 139
Wilkinson, A.	96	Zijp, L.J.	236
Wilkinson, W.	88	Zimmerman, R.	217
Williams, J.	140	Zimmermann, F.	238, 231
Williams, T.	205	Zinkin, H.	106, 139, 323
Winfield, R.	42	Zoberi, I.	53
Wisser, L.	215	Zogal, P.	324
Woern, H.	315	Zumbe, J.	212
Wojcik, M.	268, 280	Zuniga, C.	47, 261, 317
Wolfram, R.	126	Zurita Herrera, M.	301
Wong, J.	116	Zurita, M.	84
		Zwierzchowski, G.	94, 326, 328

